AptarGroup (ATR) 10-Q26 Jul 242024 Q2 Quarterly reportFinancial data

Company Profile

COVER

COVER - shares	6 Months Ended
COVER - shares	Jun. 30, 2024	Jul. 22, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	1-11846
Entity Registrant Name	AptarGroup, Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3853103
Entity Address, Address Line One	265 EXCHANGE DRIVE
Entity Address, Address Line Two	SUITE 301
Entity Address, City or Town	CRYSTAL LAKE
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60014
City Area Code	815
Local Phone Number	477-0424
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	ATR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		66,388,414
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000896622
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net Sales	$ 910,063	$ 895,906	$ 1,825,511	$ 1,755,973
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	567,440	573,711	1,150,196	1,131,133
Selling, research & development and administrative	149,330	141,428	302,110	289,351
Depreciation and amortization	64,968	62,267	129,317	121,526
Restructuring initiatives	2,315	1,943	5,795	13,467
Total Operating Expenses	784,053	779,349	1,587,418	1,555,477
Operating Income	126,010	116,557	238,093	200,496
Other (Expense) Income:
Interest expense	(10,061)	(9,688)	(20,236)	(19,916)
Interest income	3,102	648	6,000	1,320
Net investment (loss) gain	(140)	2,891	452	3,079
Equity in results of affiliates	130	643	(91)	512
Miscellaneous expense, net	(795)	(173)	(1,654)	(1,344)
Total Other Expense	(7,764)	(5,679)	(15,529)	(16,349)
Income before Income Taxes	118,246	110,878	222,564	184,147
Provision for Income Taxes	27,788	27,831	49,173	46,514
Net Income	90,458	83,047	173,391	137,633
Net (Gain) Loss Attributable to Noncontrolling Interests	(4)	25	167	203
Net Income Attributable to AptarGroup, Inc.	$ 90,454	$ 83,072	$ 173,558	$ 137,836
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic (in dollars per share)	$ 1.36	$ 1.27	$ 2.62	$ 2.11
Diluted (in dollars per share)	$ 1.34	$ 1.24	$ 2.57	$ 2.07
Average Number of Shares Outstanding:
Basic (in shares)	66,312	65,568	66,188	65,470
Diluted (in shares)	67,575	66,855	67,509	66,748
Dividends per Common Share (in dollars per share)	$ 0.41	$ 0.38	$ 0.82	$ 0.76

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Net Income	$ 90,458	$ 83,047	$ 173,391	$ 137,633
Other Comprehensive (Loss) Income:
Foreign currency translation adjustments	(24,009)	(1,749)	(66,111)	23,875
Changes in derivative gains (losses), net of tax	2,601	(3,764)	5,509	(5,131)
Defined benefit pension plan, net of tax
Actuarial gain, net of tax	22	7	102	68
Amortization of prior service cost included in net income, net of tax	20	33	40	65
Amortization of net loss included in net income, net of tax	181	162	364	322
Total defined benefit pension plan, net of tax	223	202	506	455
Total other comprehensive (loss) income	(21,185)	(5,311)	(60,096)	19,199
Comprehensive Income	69,273	77,736	113,295	156,832
Comprehensive Loss Attributable to Noncontrolling Interests	308	896	708	231
Comprehensive Income Attributable to AptarGroup, Inc.	$ 69,581	$ 78,632	$ 114,003	$ 157,063

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Assets
Cash and equivalents	$ 221,492	$ 223,643
Short-term investments	2,399	0
Accounts and notes receivable, less current expected credit loss (“CECL”) of $13,711 in 2024 and $16,217 in 2023	737,764	677,822
Inventories	484,608	513,053
Prepaid and other	147,387	134,761
Total Current Assets	1,593,650	1,549,279
Land	29,194	30,090
Buildings and improvements	752,024	748,897
Machinery and equipment	3,158,933	3,183,097
Property, Plant and Equipment, Gross	3,940,151	3,962,084
Less: Accumulated depreciation	(2,473,875)	(2,484,021)
Property, Plant and Equipment, Net	1,466,276	1,478,063
Investments in equity securities	48,527	49,203
Goodwill	950,075	963,418
Intangible assets, net	258,330	283,211
Operating lease right-of-use assets	58,829	59,074
Miscellaneous	77,570	69,642
Total Other Assets	1,393,331	1,424,548
Total Assets	4,453,257	4,451,890
Current Liabilities:
Notes payable, revolving credit facility and overdrafts	136,320	81,794
Current maturities of long-term obligations, net of unamortized debt issuance costs	269,399	376,426
Accounts payable, accrued and other liabilities	762,390	793,089
Total Current Liabilities	1,168,109	1,251,309
Long-Term Obligations, net of unamortized debt issuance costs	681,532	681,188
Deferred income taxes	14,752	19,016
Retirement and deferred compensation plans	66,323	62,795
Operating lease liabilities	43,336	45,267
Deferred and other non-current liabilities	68,990	71,017
Commitments and contingencies	0	0
Total Deferred Liabilities and Other	193,401	198,095
AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 72.1 million and 71.7 million shares issued as of June 30, 2024 and December 31, 2023, respectively	721	717
Capital in excess of par value	1,082,560	1,044,429
Retained earnings	2,229,377	2,109,816
Accumulated other comprehensive loss	(368,524)	(308,734)
Less: Treasury stock at cost, 5.8 million and 5.8 million shares as of June 30, 2024 and December 31, 2023	(547,685)	(539,404)
Total AptarGroup, Inc. Stockholders’ Equity	2,396,449	2,306,824
Noncontrolling interests in subsidiaries	13,766	14,474
Total Stockholders’ Equity	2,410,215	2,321,298
Total Liabilities and Stockholders’ Equity	$ 4,453,257	$ 4,451,890

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands, shares in Millions	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts and notes receivable, allowance for credit loss	$ 13,711	$ 16,217
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	199	199
Common stock, shares issued (in shares)	72.1	71.7
Treasury stock (in shares)	5.8	5.8

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock Par Value	Treasury Stock	Capital in Excess of Par Value	Non- Controlling Interest
Beginning balance at Dec. 31, 2022	$ 2,068,204	$ 1,929,240	$ (341,366)	$ 709	$ (503,266)	$ 968,618	$ 14,269
Increase (Decrease) in Stockholders' Equity
Net income (loss)	137,633	137,836					(203)
Foreign currency translation adjustments	23,875	(226)	24,129				(28)
Changes in unrecognized pension gains and related amortization, net of tax	455		455
Changes in derivative gains (losses), net of tax	(5,131)		(5,131)
Stock awards and option exercises	42,214			4	5,821	36,389
Cash dividends declared on common stock	(49,785)	(49,785)
Treasury stock purchased	(29,039)				(29,039)
Ending balance at Jun. 30, 2023	2,188,426	2,017,065	(321,913)	713	(526,484)	1,005,007	14,038
Beginning balance at Mar. 31, 2023	2,127,757	1,958,930	(317,473)	711	(520,329)	990,984	14,934
Increase (Decrease) in Stockholders' Equity
Net income (loss)	83,047	83,072					(25)
Foreign currency translation adjustments	(1,749)		(878)				(871)
Changes in unrecognized pension gains and related amortization, net of tax	202		202
Changes in derivative gains (losses), net of tax	(3,764)		(3,764)
Stock awards and option exercises	17,180			2	3,155	14,023
Cash dividends declared on common stock	(24,937)	(24,937)
Treasury stock purchased	(9,310)				(9,310)
Ending balance at Jun. 30, 2023	2,188,426	2,017,065	(321,913)	713	(526,484)	1,005,007	14,038
Beginning balance at Dec. 31, 2023	2,321,298	2,109,816	(308,734)	717	(539,404)	1,044,429	14,474
Increase (Decrease) in Stockholders' Equity
Net income (loss)	173,391	173,558					(167)
Foreign currency translation adjustments	(66,111)	235	(65,805)				(541)
Changes in unrecognized pension gains and related amortization, net of tax	506		506
Changes in derivative gains (losses), net of tax	5,509		5,509
Stock awards and option exercises	46,988			4	8,853	38,131
Cash dividends declared on common stock	(54,232)	(54,232)
Treasury stock purchased	(17,134)				(17,134)
Ending balance at Jun. 30, 2024	2,410,215	2,229,377	(368,524)	721	(547,685)	1,082,560	13,766
Beginning balance at Mar. 31, 2024	2,362,933	2,165,858	(347,418)	720	(545,630)	1,075,329	14,074
Increase (Decrease) in Stockholders' Equity
Net income (loss)	90,458	90,454					4
Foreign currency translation adjustments	(24,009)	233	(23,930)				(312)
Changes in unrecognized pension gains and related amortization, net of tax	223		223
Changes in derivative gains (losses), net of tax	2,601		2,601
Stock awards and option exercises	10,235			1	3,003	7,231
Cash dividends declared on common stock	(27,168)	(27,168)
Treasury stock purchased	(5,058)				(5,058)
Ending balance at Jun. 30, 2024	$ 2,410,215	$ 2,229,377	$ (368,524)	$ 721	$ (547,685)	$ 1,082,560	$ 13,766

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities:
Net Income	$ 173,391	$ 137,633
Adjustments to reconcile net income to net cash provided by operations:
Depreciation	107,643	99,432
Amortization	21,674	22,094
Stock-based compensation	27,553	25,433
(Release) provision for CECL	(1,997)	2,877
Loss (gain) on disposition of fixed assets	126	(2,945)
Net gain on remeasurement of equity securities	(452)	(3,079)
Deferred income taxes	(8,139)	(6,321)
Defined benefit plan expense	7,407	7,098
Equity in results of affiliates	91	(512)
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables	(78,360)	(28,287)
Inventories	13,713	(18,569)
Prepaid and other current assets	(13,797)	(32,535)
Accounts payable, accrued and other liabilities	2,909	687
Income taxes payable	(1,248)	(12,869)
Retirement and deferred compensation plan liabilities	(10,167)	(2,812)
Other changes, net	(4,435)	(5,124)
Net Cash Provided by Operations	235,912	182,201
Cash Flows from Investing Activities:
Capital expenditures	(143,866)	(155,012)
Proceeds from sale of property, plant and equipment	1,020	3,542
Purchase of short-term investments	(2,242)	(21)
Acquisition of businesses, net of cash acquired and release of escrow	0	(10,910)
Acquisition of intangible assets, net	0	(1,300)
Notes receivable, net	102	92
Net Cash Used by Investing Activities	(144,986)	(163,609)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts	14,178	19,063
Repayments of notes payable and overdrafts	(8,841)	(22,631)
Proceeds and (repayments) of short term revolving credit facility, net	49,338	61,053
Proceeds from long-term obligations	3,062	261
Repayments of long-term obligations	(103,177)	(16,338)
Payment of contingent consideration obligation	0	(22,750)
Dividends paid	(54,232)	(49,785)
Proceeds from stock option exercises	27,797	24,342
Purchase of treasury stock	(17,134)	(29,039)
Net Cash Used by Financing Activities	(89,009)	(35,824)
Effect of Exchange Rate Changes on Cash	(4,068)	(3,517)
Net Decrease in Cash and Equivalents and Restricted Cash	(2,151)	(20,749)
Cash and Equivalents and Restricted Cash at Beginning of Period	223,643	142,732
Cash and Equivalents and Restricted Cash at End of Period	221,492	121,983
Cash and equivalents	221,492	120,983
Restricted cash included in prepaid and other	0	1,000
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$ 221,492	$ 121,983

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Jun. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup,” “Aptar,” “Company,” “we,” “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year. ADOPTION OF RECENT ACCOUNTING STANDARDS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) in our revolving credit facility. In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We are evaluating the impact of the standard on our segment reporting disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and are required to be applied prospectively with the option of retrospective application. We are evaluating the impact of the standard on our income tax disclosures. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements. INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create temporary differences between the tax basis of an asset or liability and our reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. As of June 30, 2024, under currently enacted laws, we do not have a balance of foreign earnings that will be subject to U.S. taxation upon repatriation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. See Note 5 - Income Taxes for more information. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and government bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements. ASSETS HELD FOR SALE Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Condensed Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale. As of June 30, 2024, one building is still held for sale and expected to be sold by year end 2024. SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program (“SCF”) across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions. All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of June 30, 2024, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $36.2 million. Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain. To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered a third party alternative for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.

REVENUE

REVENUE	6 Months Ended
REVENUE	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE In prior years, our geographic revenue disclosure was based on shipped from location. Beginning in 2024, we have started to report our geographic sales based on shipped to locations to give the reader a better understanding of the geographies we serve. Revenue by segment and geography based on shipped to locations for the three and six months ended June 30, 2024 and 2023 were as follows: For the Three Months Ended June 30, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 207,493 $ 138,734 $ 13,301 $ 55,005 $ 414,533 Aptar Beauty 190,740 66,618 42,207 21,922 321,487 Aptar Closures 51,894 84,468 22,283 15,398 174,043 Total $ 450,127 $ 289,820 $ 77,791 $ 92,325 $ 910,063 For the Three Months Ended June 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 208,062 $ 113,613 $ 15,669 $ 53,356 $ 390,700 Aptar Beauty 211,774 56,940 39,501 21,372 329,587 Aptar Closures 58,810 81,400 20,879 14,530 175,619 Total $ 478,646 $ 251,953 $ 76,049 $ 89,258 $ 895,906 For the Six Months Ended June 30, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 419,668 $ 264,544 $ 25,923 $ 111,691 $ 821,826 Aptar Beauty 396,930 129,895 80,394 41,588 648,807 Aptar Closures 107,921 173,284 43,556 30,117 354,878 Total $ 924,519 $ 567,723 $ 149,873 $ 183,396 $ 1,825,511 For the Six Months Ended June 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 400,182 $ 228,925 $ 23,866 $ 93,773 $ 746,746 Aptar Beauty 421,126 115,928 76,066 42,856 655,976 Aptar Closures 116,137 166,168 41,245 29,701 353,251 Total $ 937,445 $ 511,021 $ 141,177 $ 166,330 $ 1,755,973 We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the invoicing for the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance. The opening and closing balances of our contract asset and contract liabilities were as follows: Balance as of December 31, 2023 Balance as of June 30, 2024 Increase/ Contract asset (current) $ 18,033 $ 13,783 $ (4,250) Contract liability (current) 60,507 64,435 3,928 Contract liability (long-term) 37,756 42,102 4,346 The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during the current year against contract liabilities is $60.3 million, including $35.9 million relating to contract liabilities at the beginning of the year. Current contract assets are included within Prepaid and other, while current contract liabilities and long-term contract liabilities are included within Accounts payable, accrued and other liabilities and Deferred and other non-current liabilities, respectively, within our Condensed Consolidated Balance Sheets. Determining the Transaction Price In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled. Product Sales We primarily manufacture and sell drug and consumer product dosing, dispensing and protection technologies. The amount of consideration is typically fixed for customers. At the time of delivery, the customer is invoiced at the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer. To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale. There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the output method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced. As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties. Tooling Sales We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the input method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any significant payment terms as payment is typically either received during the mold-build process or shortly after completion. In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of June 30, 2024 or December 31, 2023. Service Sales We also provide services to our customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Milestone deliverables and upfront payments are tied to specific performance obligations and recognized upon satisfaction of the individual performance obligation. Royalty Revenue We determine the amount and timing of royalty revenue based on our contractual agreements with customers. We recognize royalty revenue when earned under the terms of the agreements and when we consider realization of payment to be probable. Contract Costs We do not incur significant costs to obtain or fulfill revenue contracts. Credit Risk We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating, or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review. We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.

INVENTORIES

INVENTORIES	6 Months Ended
INVENTORIES	Jun. 30, 2024
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, by component net of reserves, consisted of: June 30, December 31, Raw materials $ 131,954 $ 145,798 Work in process 176,527 176,191 Finished goods 176,127 191,064 Total $ 484,608 $ 513,053

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	6 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amount of goodwill for the six months ended June 30, 2024 by reporting segment were as follows: Aptar Aptar Aptar Closures Total Balance as of December 31, 2023 $ 508,447 $ 287,097 $ 167,874 $ 963,418 Foreign currency exchange effects (10,089) (2,585) (669) (13,343) Balance as of June 30, 2024 $ 498,358 $ 284,512 $ 167,205 $ 950,075 The table below shows a summary of intangible assets as of June 30, 2024 and December 31, 2023. June 30, 2024 December 31, 2023 Weighted Average Amortization Period (Years) Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 10.0 $ 7,139 $ (1,968) $ 5,171 $ 7,362 $ (1,754) $ 5,608 Acquired technology 11.2 140,643 (75,255) 65,388 142,837 (70,520) 72,317 Customer relationships 13.6 305,349 (135,198) 170,151 308,889 (124,648) 184,241 Trademarks and trade names 8.0 43,078 (35,188) 7,890 43,932 (33,368) 10,564 License agreements and other 32.7 16,846 (7,116) 9,730 17,213 (6,732) 10,481 Total intangible assets 13.5 $ 513,055 $ (254,725) $ 258,330 $ 520,233 $ (237,022) $ 283,211 Aggregate amortization expense for the intangible assets above for the quarters ended June 30, 2024 and 2023 was $10,351 and $11,131, respectively. Aggregate amortization expense for the intangible assets above for the six months ended June 30, 2024 and 2023 was $21,674 and $22,094, respectively. As of June 30, 2024, future estimated amortization expense for the years ending December 31 is as follows: 2024 $ 20,276 (remaining estimated amortization for 2024) 2025 39,880 2026 37,563 2027 30,410 2028 21,174 Thereafter 109,027 Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of June 30, 2024.

INCOME TAXES

INCOME TAXES	6 Months Ended
INCOME TAXES	Jun. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full-year taxes, adjusted for the impact of discrete quarterly items. The Organization for Economic Co-operation and Development released Model Global Anti-Base Erosion rules under Pillar Two. Certain countries in which we operate have enacted laws implementing aspects of Pillar Two beginning in 2024. These enacted laws relate to the Pillar Two Income Inclusion Rule and Qualified Domestic Minimum Top-Up Tax with an effective date in 2024. We have analyzed the provisions in the applicable jurisdictions and provided for the appropriate tax amounts. We do not expect a material impact from the implementation of these rules for 2024 but we will continue to monitor future legislations for additional guidance. The effective tax rate for the three months ended June 30, 2024 and 2023, respectively, was 23.5% and 25.1%. The effective tax rate for the three months ended June 30, 2024 reflects a favorable mix of earnings. The effective tax rate for the six months ended June 30, 2024 and 2023, respectively, was 22.1% and 25.3%. The effective tax rate for the six months ended June 30, 2024 reflects a favorable mix of earnings, increased tax benefits from share-based compensation and tax incentives in certain non-U.S. jurisdictions from intellectual property development activities.

DEBT

DEBT	6 Months Ended
DEBT	Jun. 30, 2024
Debt Disclosure [Abstract]
DEBT	DEBT Notes Payable, Revolving Credit Facility and Overdrafts At June 30, 2024 and December 31, 2023, our notes payable, revolving credit facility and overdrafts consisted of the following: June 30, December 31, Revolving credit facility 6.44% $ 130,000 $ 80,662 Overdrafts 3.08% to 6.00% 6,320 1,132 $ 136,320 $ 81,794 A of June 30, 2024, Aptar had a revolving credit facility (the “revolving credit facility”) with a syndicate of banks which matured in June 2026. The revolving credit facility was subject to a maximum of two one-year extensions in certain circumstances and provided for unsecured financing of up to $600 million available in the U.S. and to our wholly-owned UK subsidiary. The revolving credit facility could be drawn in various currencies including USD, EUR, GBP, and CHF to the equivalent of $600 million, which may be increased by up to $300 million subject to the satisfaction of certain conditions. As of June 30, 2024, $130 million was utilized under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of December 31, 2023, $36.5 million and €40.0 million ($44.2 million) was utilized under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. On July 2, 2024, we entered into a new amended and restated multi-currency revolving credit facility (the “amended revolving credit facility”) with a syndicate of banks to replace the current revolving credit facility. The amended revolving credit facility matures in July 2029, subject to a maximum of two one-year extensions in certain circumstances, and provides for unsecured financing of up to $600 million available in the U.S. and to our wholly-owned UK subsidiary. The amended revolving credit facility can be drawn in various currencies including USD, EUR, GBP, and CHF to the equivalent of $600 million, which may be increased by up to $300 million subject to the satisfaction of certain conditions. On July 2, 2024, we entered into a term loan with a syndicate of banks (the “Term Loan”). The Term Loan matures in July 2027 and enables drawings on the loan until September 30, 2024 and provides for unsecured financing of up to $330 million available in the U.S. Funds are expected to be used to refinance near-term maturities and for general corporate purposes. There are no compensating balance requirements associated with our amended revolving credit facility. Each borrowing under the amended revolving credit facility will bear interest at rates based on SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The amended revolving credit facility also provides mechanics relating to a transition away from designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the amended revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the amended revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. Aptar has an unsecured money market borrowing arrangement to provide short term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of June 30, 2024 or December 31, 2023. Long-Term Obligations On February 26, 2024, we repaid in full the $100 million 3.49% Senior Notes that were due in February 2024. At June 30, 2024 and December 31, 2023, our long-term obligations consisted of the following: June 30, 2024 December 31, 2023 Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2030 $ 16,607 $ 14,988 Senior unsecured notes 3.4%, due in 2024 50,000 50,000 Senior unsecured notes 3.5%, due in 2024 — 100,000 Senior unsecured notes 1.2%, due in 2024 214,220 220,810 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million 399,206 399,154 Finance Lease Liabilities 24,376 26,478 Unamortized debt issuance costs (3,478) (3,816) $ 950,931 $ 1,057,614 Current maturities of long-term obligations (269,399) (376,426) Total long-term obligations $ 681,532 $ 681,188 The €200 million ($214 million) senior unsecured notes were due on July 19, 2024, and have been repaid from a drawdown of our amended revolving credit facility. The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 7, due annually from the current balance sheet date for the next five years and thereafter are: Year One $ 266,123 Year Two 134,218 Year Three 130,330 Year Four 73 Year Five 42 Thereafter 399,247 Covenants Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at June 30, 2024 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.29 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 16.97 to 1.00 ________________________________________ (1)

LEASES

LEASES	6 Months Ended
LEASES	Jun. 30, 2024
Leases [Abstract]
LEASES	LEASES We lease certain warehouse, plant and office facilities, as well as certain equipment, under non-cancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense, while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses. The components of lease expense for the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating lease cost $ 4,854 $ 5,277 $ 9,735 $ 10,691 Finance lease cost: Amortization of right-of-use assets $ 1,591 $ 867 $ 3,261 $ 1,778 Interest on lease liabilities 302 295 598 594 Total finance lease cost $ 1,893 $ 1,162 $ 3,859 $ 2,372 Short-term lease and variable lease costs $ 4,998 $ 5,197 $ 10,196 $ 10,109 Supplemental cash flow information related to leases were as follows: Six Months Ended June 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9,754 $ 10,640 Operating cash flows from finance leases 647 600 Financing cash flows from finance leases 1,821 1,649 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 12,059 $ 6,597 Finance leases 311 352
LEASES	LEASES We lease certain warehouse, plant and office facilities, as well as certain equipment, under non-cancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense, while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses. The components of lease expense for the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating lease cost $ 4,854 $ 5,277 $ 9,735 $ 10,691 Finance lease cost: Amortization of right-of-use assets $ 1,591 $ 867 $ 3,261 $ 1,778 Interest on lease liabilities 302 295 598 594 Total finance lease cost $ 1,893 $ 1,162 $ 3,859 $ 2,372 Short-term lease and variable lease costs $ 4,998 $ 5,197 $ 10,196 $ 10,109 Supplemental cash flow information related to leases were as follows: Six Months Ended June 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9,754 $ 10,640 Operating cash flows from finance leases 647 600 Financing cash flows from finance leases 1,821 1,649 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 12,059 $ 6,597 Finance leases 311 352

RETIREMENT AND DEFERRED COMPENS

RETIREMENT AND DEFERRED COMPENSATION PLANS	6 Months Ended
RETIREMENT AND DEFERRED COMPENSATION PLANS	Jun. 30, 2024
Retirement Benefits [Abstract]
RETIREMENT AND DEFERRED COMPENSATION PLANS	RETIREMENT AND DEFERRED COMPENSATION PLANS We have various noncontributory retirement plans covering certain of our domestic and foreign employees. Benefits under our retirement plans are based on participants’ years of service and annual compensation as defined by each plan. Annual cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Certain pension commitments under our foreign plans are also funded according to local requirements or at our discretion. Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date. Components of Net Periodic Benefit Cost: Domestic Plans Foreign Plans Three Months Ended June 30, 2024 2023 2024 2023 Service cost $ 2,366 $ 2,410 $ 1,603 $ 1,487 Interest cost 2,252 2,157 867 917 Expected return on plan assets (3,130) (3,095) (558) (589) Amortization of net loss — — 257 229 Amortization of prior service cost — — 26 45 Net periodic benefit cost $ 1,488 $ 1,472 $ 2,195 $ 2,089 Domestic Plans Foreign Plans Six Months Ended June 30, 2024 2023 2024 2023 Service cost $ 4,731 $ 4,819 $ 3,233 $ 2,957 Interest cost 4,484 4,315 1,742 1,820 Expected return on plan assets (6,231) (6,189) (1,122) (1,169) Amortization of net loss — — 516 457 Amortization of prior service cost — — 54 88 Net periodic benefit cost $ 2,984 $ 2,945 $ 4,423 $ 4,153 The components of net periodic benefit cost, other than the service cost component, are included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income. Employer Contributions We currently have no minimum funding requirements for our domestic and foreign plans. There were no contributions to our domestic defined benefit plans during the six months ended June 30, 2024 and we do not expect significant payments during the rest of 2024. We contributed $0.7 million to our foreign defined benefit plans during the six months ended June 30, 2024 and do not expect additional significant contributions during the rest of 2024.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	6 Months Ended
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	Jun. 30, 2024
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME Changes in Accumulated Other Comprehensive (Loss) Income by Component: Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Other comprehensive income (loss) before reclassifications 24,129 68 (5,131) 19,066 Amounts reclassified from accumulated other comprehensive income — 387 — 387 Net current-period other comprehensive income (loss) 24,129 455 (5,131) 19,453 Balance - June 30, 2023 $ (304,611) $ (5,496) $ (11,806) $ (321,913) Balance - December 31, 2023 $ (280,082) $ (11,891) $ (16,761) $ (308,734) Other comprehensive (loss) income before reclassifications (65,805) 102 5,509 (60,194) Amounts reclassified from accumulated other comprehensive income — 404 — 404 Net current-period other comprehensive (loss) income (65,805) 506 5,509 (59,790) Balance - June 30, 2024 $ (345,887) $ (11,385) $ (11,252) $ (368,524) Reclassifications Out of Accumulated Other Comprehensive (Loss) Income: Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Three Months Ended June 30, 2024 2023 Defined Benefit Pension Plans Amortization of net loss $ 257 $ 229 (1) Amortization of prior service cost 26 45 (1) 283 274 Total before tax (82) (79) Tax impact $ 201 $ 195 Net of tax Total reclassifications for the period $ 201 $ 195 Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Six Months Ended June 30, 2024 2023 Defined Benefit Pension Plans Amortization of net loss $ 516 $ 457 (1) Amortization of prior service cost 54 88 (1) 570 545 Total before tax (166) (158) Tax impact $ 404 $ 387 Net of tax Total reclassifications for the period $ 404 $ 387 ______________________________________________ (1) These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	6 Months Ended
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks. For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets (See Note 11 - Fair Value). Cash Flow Hedge For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows. Net Investment Hedge A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar has an additive effect on our financial condition and results of operations. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect. In some cases we maintain debt in these subsidiaries to offset the net asset exposure. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction. On July 6, 2022, we entered into a seven year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Notes due March 2032, which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203 million of fixed-rate 3.60% USD debt to €200 million of fixed-rate 2.5224% euro debt. We pay semi-annual fixed rate interest payments on the euro notional amount of €2.5 million and receive semi-annual fixed rate interest payments on the USD notional amount of $3.7 million. This swap has been designated as a net investment hedge to effectively hedge the foreign exchange risk associated with €200 million of our euro denominated net assets. We elected the spot method for recording the net investment hedge. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense in the Condensed Consolidated Statements of Income. Gains and losses resulting from the fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive (loss) income as the swaps are effective in hedging the designated risk. As of June 30, 2024, the fair value of the cross currency swap was a $14.9 million liability. The swap agreement will mature on September 15, 2029. Other As of June 30, 2024, we have recorded the fair value of foreign currency forward exchange contracts of $0.9 million in prepaid and other and $0.6 million in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. All forward exchange contracts outstanding as of June 30, 2024 had an aggregate notional contract amount of $73.0 million. Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 June 30, 2024 December 31, 2023 Balance Sheet Location Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 949 $ — $ 386 $ — $ 949 $ — $ 386 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 646 $ — $ 221 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 14,901 — 22,199 — $ 14,901 $ 646 $ 22,199 $ 221 __________________________ (1) This cross currency swap agreement is composed of both an interest component and a foreign exchange component. The Effect of Derivatives Designated as Hedging Instruments on Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended June 30, 2024 and 2023 Derivatives Designated as Hedging Instruments Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2024 2023 2024 2023 Cross currency swap agreement: Interest component $ — $ — Interest expense $ — $ — $ (10,061) Foreign exchange component 2,601 3,763 Miscellaneous, net — — (795) $ 2,601 $ 3,763 $ — $ — The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Six Months Ended June 30, 2024 and 2023 Derivatives Designated as Hedging Instruments Amount of Gain Location of Gain Recognized Amount of Gain Total Amount of Affected Income Statement Line Item 2024 2023 2024 2023 Cross currency swap agreement: Interest component $ — $ — Interest expense $ — $ — $ (20,236) Foreign exchange component 5,509 (5,131) Miscellaneous, net — — (1,654) $ 5,509 $ (5,131) $ — $ — The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2024 and 2023 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ 437 $ 59 $ 437 $ 59 The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2024 and 2023 Derivatives Not Designated Location of Loss Recognized Amount of Loss 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ 140 $ (800) $ 140 $ (800) Gross Amounts Offset in the Statement of Financial Position Net Amounts Presented in the Statement of Financial Position Gross Amounts not Offset in the Statement of Financial Position Gross Amount Financial Instruments Cash Collateral Received Net Amount June 30, 2024 Derivative Assets $ 949 — $ 949 — — $ 949 Total Assets $ 949 — $ 949 — — $ 949 Derivative Liabilities $ 15,547 — $ 15,547 — — $ 15,547 Total Liabilities $ 15,547 — $ 15,547 — — $ 15,547 December 31, 2023 Derivative Assets $ 386 — $ 386 — — $ 386 Total Assets $ 386 — $ 386 — — $ 386 Derivative Liabilities $ 22,420 — $ 22,420 — — $ 22,420 Total Liabilities $ 22,420 — $ 22,420 — — $ 22,420

FAIR VALUE

FAIR VALUE	6 Months Ended
FAIR VALUE	Jun. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows: • Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities. • Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. • Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability. As of June 30, 2024, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,725 $ 1,725 $ — $ — Foreign exchange contracts (2) 949 — 949 — Convertible notes (3) 5,650 — — 5,650 Total assets at fair value $ 8,324 $ 1,725 $ 949 $ 5,650 Liabilities Foreign exchange contracts (2) $ 646 $ — $ 646 $ — Cross currency swap contract (2) 14,901 — 14,901 — Total liabilities at fair value $ 15,547 $ — $ 15,547 $ — As of December 31, 2023, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,106 $ 1,106 $ — $ — Foreign exchange contracts (2) 386 — 386 — Convertible note (3) 5,650 — — 5,650 Total assets at fair value $ 7,142 $ 1,106 $ 386 $ 5,650 Liabilities Foreign exchange contracts (2) $ 221 $ — $ 221 $ — Cross currency swap contract (2) 22,199 — 22,199 — Total liabilities at fair value $ 22,420 $ — $ 22,420 $ — ________________________________________________ (1) Investment in PureCycle Technologies (“PCT” or “PureCycle”). See Note 18 – Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. (3) Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Condensed Consolidated Balance Sheets. The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $614.5 million as of June 30, 2024 and $620.7 million as of December 31, 2023.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows. Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of June 30, 2024 and December 31, 2023. We are periodically subject to loss contingencies resulting from custom duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $13 million in principal and $5 million to $6 million for interest and penalties. We are currently defending our position with respect to these claims in the respected administrative procedures. Due to uncertainty in the amount of the assessment and the timing of our appeal, no liability is recorded as of June 30, 2024.

STOCK REPURCHASE PROGRAM

STOCK REPURCHASE PROGRAM	6 Months Ended
STOCK REPURCHASE PROGRAM	Jun. 30, 2024
Equity [Abstract]
STOCK REPURCHASE PROGRAM	STOCK REPURCHASE PROGRAM On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. During the three and six months ended June 30, 2024, we repurchased approximately 34 thousand shares for $5.1 million and 120 thousand shares for $17.1 million, respectively. During the three and six months ended June 30, 2023, we repurchased approximately 81 thousand shares for $9.3 million and 252 thousand shares for $29.0 million, respectively. As of June 30, 2024, there was $43.5 million of authorized share repurchases remaining under the existing authorization.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
STOCK-BASED COMPENSATION	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. For awards granted in the first quarter of 2023 and thereafter, our performance-based RSUs will vest solely based on our return on invested capital (“ROIC”). Award share payouts depend on the extent to which the ROIC performance goal has been achieved, but the final payout is adjusted by a total shareholder return (“TSR”) modifier. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest on or around the first anniversary of the date of grant. The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Six Months Ended June 30, 2024 2023 Fair value per stock award $ 145.79 $ 116.17 Grant date stock price $ 141.00 $ 111.38 Assumptions: Aptar's stock price expected volatility 18.80 % 20.00 % Expected average volatility of peer companies 34.80 % 39.70 % Correlation assumption 30.70 % 33.30 % Risk-free interest rate 4.51 % 3.83 % Dividend yield assumption 1.16 % 1.36 % A summary of RSU activity as of June 30, 2024 and changes during the six month period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2024 335,874 $ 115.15 514,383 $ 130.10 Granted 117,660 136.61 129,614 145.79 Vested (173,168) 119.27 (97,794) 162.33 Forfeited (2,352) 117.67 (26,886) 146.76 Nonvested at June 30, 2024 278,014 $ 121.51 519,317 $ 127.13 Included in the time-based RSU activity for the six months ended June 30, 2024 are 10,208 units granted to non-employee directors and 11,508 units vested related to non-employee directors. Six Months Ended June 30, 2024 2023 Compensation expense $ 21,966 $ 22,008 Fair value of units vested 34,991 27,178 Intrinsic value of units vested 38,040 31,809 The actual tax benefit realized for the tax deduction from RSUs was approximately $7.1 million and $5.4 million in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, there was $53.3 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 2.0 years. Historically we issued stock options to our employees and non-employee directors. We did not issue stock options between 2019 and 2022. Stock options were reinstituted in 2023 and valued based on the Black-Scholes model and generally vest ratably over three years and expire 10 years after grant. The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans were $36.07 per share for all employees during the first six months of 2024. The weighted-average fair value of stock options granted under the stock awards plans were $19.84 and $24.23 per share for executive officers and all other employees, respectively, during the first six months of 2023. Aptar executive officers received stock options with an exercise price that was 110% of the closing market price on the date of grant. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: Stock Award Plans: Six Months Ended June 30, 2024 2023 Dividend Yield 1.28 % 1.41 % Expected Stock Price Volatility 17.03 % 16.55 % Risk-free Interest Rate 4.51 % 3.57 % Expected Life of Option (years) 7.0 7.0 A summary of option activity under our stock plans during the six months ended June 30, 2024 is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2024 2,182,784 $ 80.63 19,000 $ 66.59 Granted 249,805 141.00 — — Exercised (377,602) 70.66 (19,000) 66.59 Forfeited or expired (5,185) 93.42 — — Outstanding at June 30, 2024 2,049,802 $ 89.80 — $ — Exercisable at June 30, 2024 1,593,918 $ 78.35 — $ — Weighted-Average Remaining Contractual Term (Years): Outstanding at June 30, 2024 4.2 0.0 Exercisable at June 30, 2024 2.7 0.0 Aggregate Intrinsic Value: Outstanding at June 30, 2024 $ 110,862 $ — Exercisable at June 30, 2024 $ 104,452 $ — Intrinsic Value of Options Exercised During the Six Months Ended: June 30, 2024 $ 25,454 $ 1,394 June 30, 2023 $ 16,886 $ 854 Six Months Ended June 30, 2024 2023 Compensation expense (included in SG&A) $ 4,376 $ 3,147 Compensation expense (included in Cost of sales) 492 278 Compensation expense, Total $ 4,868 $ 3,425 Compensation expense, net of tax 5,272 3,425 Grant date fair value of options vested 2,306 — The increase in stock option expense is due to the newly issued options as discussed above. Cash received from option exercises for the six months ended June 30, 2024 and 2023 was approximately $27.8 million and $24.3 million, respectively. The actual tax benefit realized for the tax deduction from option exercises was approximately $6.2 million and $4.3 million in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, there was $6.0 million of total unrecognized compensation cost relating to stock option awards which is expected to be recognized over a weighted-average period of 2.3 years.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
EARNINGS PER SHARE	Jun. 30, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, 2024 June 30, 2023 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 90,454 $ 90,454 $ 83,072 $ 83,072 Average equivalent shares Shares of common stock 66,312 66,312 65,568 65,568 Effect of dilutive stock-based compensation Stock options 774 — 871 — Restricted stock 489 — 416 — Total average equivalent shares 67,575 66,312 66,855 65,568 Net income per share $ 1.34 $ 1.36 $ 1.24 $ 1.27 Six Months Ended June 30, 2024 June 30, 2023 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 173,558 $ 173,558 $ 137,836 $ 137,836 Average equivalent shares Shares of common stock 66,188 66,188 65,470 65,470 Effect of dilutive stock-based compensation Stock options 783 — 889 — Restricted stock 538 — 389 — Total average equivalent shares 67,509 66,188 66,748 65,470 Net income per share $ 2.57 $ 2.62 $ 2.07 $ 2.11

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
SEGMENT INFORMATION	Jun. 30, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION We are organized into three reporting segments. Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Aptar Pharma segment. Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Aptar Beauty segment. Operations that sell dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets form our Aptar Closures segment. Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is named primarily for a single product platform that serves all available markets. The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2023. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Financial information regarding our reporting segments is shown below: Three Months Ended Six Months Ended 2024 2023 2024 2023 Total Sales: Aptar Pharma $ 414,783 $ 391,010 $ 822,273 $ 747,121 Aptar Beauty 328,700 338,404 663,580 671,742 Aptar Closures 176,981 177,471 359,678 357,910 Total Sales $ 920,464 $ 906,885 $ 1,845,531 $ 1,776,773 Less: Intersegment Sales: Aptar Pharma $ 250 $ 310 $ 447 $ 375 Aptar Beauty 7,213 8,817 14,773 15,766 Aptar Closures 2,938 1,852 4,800 4,659 Total Intersegment Sales $ 10,401 $ 10,979 $ 20,020 $ 20,800 Net Sales: Aptar Pharma $ 414,533 $ 390,700 $ 821,826 $ 746,746 Aptar Beauty 321,487 329,587 648,807 655,976 Aptar Closures 174,043 175,619 354,878 353,251 Net Sales $ 910,063 $ 895,906 $ 1,825,511 $ 1,755,973 Adjusted EBITDA (1): Aptar Pharma $ 141,488 $ 125,866 $ 273,666 $ 235,164 Aptar Beauty 44,638 43,100 85,772 80,305 Aptar Closures 27,118 27,772 54,279 53,780 Corporate & Other, unallocated (20,476) (15,501) (42,117) (34,337) Acquisition-related costs (2) (140) — (140) (255) Restructuring Initiatives (3) (2,315) (1,943) (5,795) (13,467) Net unrealized investment (loss) gain (4) (140) 2,891 452 3,079 Depreciation and amortization (64,968) (62,267) (129,317) (121,526) Interest Expense (10,061) (9,688) (20,236) (19,916) Interest Income 3,102 648 6,000 1,320 Income before Income Taxes $ 118,246 $ 110,878 $ 222,564 $ 184,147 ________________________________________________ (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 - Acquisitions and Note 18 – Investments in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the three and six months ended June 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Six Months Ended 2024 2023 2024 2023 Restructuring Initiatives by Plan: Optimization initiative $ 2,315 $ 1,943 $ 5,812 $ 13,483 Prior year initiatives — — (17) (16) Total Restructuring Initiatives $ 2,315 $ 1,943 $ 5,795 $ 13,467 Restructuring Initiatives by Segment: Aptar Pharma $ 65 $ 434 $ 89 $ 1,565 Aptar Beauty 1,199 479 3,909 9,770 Aptar Closures 893 440 1,653 962 Corporate & Other 158 590 144 1,170 Total Restructuring Initiatives $ 2,315 $ 1,943 $ 5,795 $ 13,467 (4) Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).

ACQUISITIONS

ACQUISITIONS	6 Months Ended
ACQUISITIONS	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
ACQUISITIONS	ACQUISITIONS Business Combinations On March 1, 2023, we completed the acquisition of all the outstanding capital stock of iD SCENT. Located in Lyon, France, iD SCENT is an expert producer of paper fragrance sampling solutions that present multiple sustainability features. The purchase price was approximately $9.4 million (net of $1.4 million cash acquired) and was funded with cash on hand. The results of iD SCENT have been included in the consolidated financial statements within our Aptar Beauty segment since the date of acquisition. Also on March 1, 2023, we completed the acquisition of 80% of the equity interest of Gulf Closures W.L.L. (“Gulf Closures”). Gulf Closures, located in Bahrain, is a closure manufacturer for beverage products. The purchase price for 80% ownership was approximately $1.5 million (net of $1.2 million cash acquired) and was funded with cash on hand. This values the full company equity at approximately $3.3 million and implies a non-controlling interest valued at approximately $0.7 million as of the acquisition date. The results of Gulf Closures have been included in the consolidated financial statements within our Aptar Closures segment since the date of acquisition.

INVESTMENT IN EQUITY SECURITIES

INVESTMENT IN EQUITY SECURITIES	6 Months Ended
INVESTMENT IN EQUITY SECURITIES	Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN EQUITY SECURITIES	INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following: June 30, December 31, Equity Method Investments: BTY $ 32,124 $ 33,090 Sonmol 4,546 4,751 Desotec GmbH 940 905 Other Investments: PureCycle 1,725 1,106 YAT 5,229 5,352 Loop 2,894 2,894 Others 1,069 1,105 $ 48,527 $ 49,203 Equity Method Investments Jinyu On December 10, 2023, we entered into a Share Purchase Agreement to acquire 40% of the equity interests in Ningbo Jinyu Technology Industry Co., Ltd. (referred to as “Jinyu”), a leading manufacturer of dispensing technologies in China for approximately $84 million subject to final closing conditions. This transaction is expected to close in 2024, subject to satisfaction and completion of various closing conditions. BTY On January 1, 2020, we acquired 49% of the equity interests in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32.0 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. For the six months ended June 30, 2024 and June 30, 2023, Aptar had purchases of $5.8 million and $7.6 million, respectively, from BTY. As of June 30, 2024 and December 31, 2023, approximately $2.4 million and $1.8 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets. Sonmol On April 1, 2020, we invested $5.0 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of specialty assembly machines for bulk processing for the pharmaceutical, beauty and closures markets. Other Investments In prior years, we invested, through a series of transactions, an aggregate amount of $2.9 million in preferred equity investments in Loop, a sustainability company. In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In March 2021, PureCycle became a publicly-traded company and listed its common stock on Nasdaq under the ticker symbol “PCT,” At that time, our investment in PureCycle was converted into shares of common stock of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. We have sold the following PCT shares related to the PureCycle investment: Shares Sold Proceeds Realized Gain 2021 191,349 $ 2,434 $ 2,000 2022 157,600 $ 1,599 $ 1,213 Q3 2023 510,449 $ 5,604 $ 4,188 On April 26, 2024, we received $0.2 million of equity in exchange for our resource dedication for technological partnership and support. For the three and six months ended June 30, 2024 and 2023, we recorded the following net investment gain on our investment in PureCycle: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net investment gain $ (140) $ 2,891 $ 452 $ 3,079 On July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company.

RESTRUCTURING INITIATIVES

RESTRUCTURING INITIATIVES	6 Months Ended
RESTRUCTURING INITIATIVES	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING INITIATIVES	RESTRUCTURING INITIATIVES During the third quarter of 2022, we began an initiative to better leverage our fixed cost base through growth and cost reduction measures. For the three and six months ended June 30, 2024, we recognized $2.3 million and $5.8 million of restructuring costs related to this initiative, respectively. For the three and six months ended June 30, 2023, we recognized $1.9 million and $13.5 million of restructuring costs related to this initiative, respectively. The cumulative expense incurred as of June 30, 2024 was $57.5 million. As of June 30, 2024, we have recorded the following activity associated with our optimization initiative: Beginning Reserve at December 31, 2023 Net Charges for the Six Months Ended June 30, 2024 Cash Paid Interest and Ending Reserve at June 30, 2024 Employee severance $ 27,078 $ 2,890 $ (9,179) $ (311) $ 20,478 Professional fees and other costs 2,810 2,922 (2,403) (15) 3,314 Totals $ 29,888 $ 5,812 $ (11,582) $ (326) $ 23,792

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 90,454	$ 83,072	$ 173,558	$ 137,836

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Jun. 30, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup,” “Aptar,” “Company,” “we,” “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.
ADOPTION OF RECENT ACCOUNTING STANDARDS	ADOPTION OF RECENT ACCOUNTING STANDARDS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) in our revolving credit facility. In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We are evaluating the impact of the standard on our segment reporting disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and are required to be applied prospectively with the option of retrospective application. We are evaluating the impact of the standard on our income tax disclosures. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.
INCOME TAXES	INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create temporary differences between the tax basis of an asset or liability and our reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. As of June 30, 2024, under currently enacted laws, we do not have a balance of foreign earnings that will be subject to U.S. taxation upon repatriation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. See Note 5 - Income Taxes for more information. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and government bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.
ASSETS HELD FOR SALE	ASSETS HELD FOR SALE Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Condensed Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale. As of June 30, 2024, one building is still held for sale and expected to be sold by year end 2024.
SUPPLY CHAIN FINANCE PROGRAM	SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program (“SCF”) across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions. All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of June 30, 2024, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $36.2 million. Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain. To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered a third party alternative for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.

REVENUE (Tables)

REVENUE (Tables)	6 Months Ended
REVENUE (Tables)	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of revenue by segment by geographic area	Revenue by segment and geography based on shipped to locations for the three and six months ended June 30, 2024 and 2023 were as follows: For the Three Months Ended June 30, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 207,493 $ 138,734 $ 13,301 $ 55,005 $ 414,533 Aptar Beauty 190,740 66,618 42,207 21,922 321,487 Aptar Closures 51,894 84,468 22,283 15,398 174,043 Total $ 450,127 $ 289,820 $ 77,791 $ 92,325 $ 910,063 For the Three Months Ended June 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 208,062 $ 113,613 $ 15,669 $ 53,356 $ 390,700 Aptar Beauty 211,774 56,940 39,501 21,372 329,587 Aptar Closures 58,810 81,400 20,879 14,530 175,619 Total $ 478,646 $ 251,953 $ 76,049 $ 89,258 $ 895,906 For the Six Months Ended June 30, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 419,668 $ 264,544 $ 25,923 $ 111,691 $ 821,826 Aptar Beauty 396,930 129,895 80,394 41,588 648,807 Aptar Closures 107,921 173,284 43,556 30,117 354,878 Total $ 924,519 $ 567,723 $ 149,873 $ 183,396 $ 1,825,511 For the Six Months Ended June 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 400,182 $ 228,925 $ 23,866 $ 93,773 $ 746,746 Aptar Beauty 421,126 115,928 76,066 42,856 655,976 Aptar Closures 116,137 166,168 41,245 29,701 353,251 Total $ 937,445 $ 511,021 $ 141,177 $ 166,330 $ 1,755,973
Schedule of opening and closing balances of contract assets and contract liabilities	The opening and closing balances of our contract asset and contract liabilities were as follows: Balance as of December 31, 2023 Balance as of June 30, 2024 Increase/ Contract asset (current) $ 18,033 $ 13,783 $ (4,250) Contract liability (current) 60,507 64,435 3,928 Contract liability (long-term) 37,756 42,102 4,346

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
INVENTORIES (Tables)	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of inventories, by component	Inventories, by component net of reserves, consisted of: June 30, December 31, Raw materials $ 131,954 $ 145,798 Work in process 176,527 176,191 Finished goods 176,127 191,064 Total $ 484,608 $ 513,053

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill for the six months ended June 30, 2024 by reporting segment were as follows: Aptar Aptar Aptar Closures Total Balance as of December 31, 2023 $ 508,447 $ 287,097 $ 167,874 $ 963,418 Foreign currency exchange effects (10,089) (2,585) (669) (13,343) Balance as of June 30, 2024 $ 498,358 $ 284,512 $ 167,205 $ 950,075
Schedule of amortized intangible assets	The table below shows a summary of intangible assets as of June 30, 2024 and December 31, 2023. June 30, 2024 December 31, 2023 Weighted Average Amortization Period (Years) Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 10.0 $ 7,139 $ (1,968) $ 5,171 $ 7,362 $ (1,754) $ 5,608 Acquired technology 11.2 140,643 (75,255) 65,388 142,837 (70,520) 72,317 Customer relationships 13.6 305,349 (135,198) 170,151 308,889 (124,648) 184,241 Trademarks and trade names 8.0 43,078 (35,188) 7,890 43,932 (33,368) 10,564 License agreements and other 32.7 16,846 (7,116) 9,730 17,213 (6,732) 10,481 Total intangible assets 13.5 $ 513,055 $ (254,725) $ 258,330 $ 520,233 $ (237,022) $ 283,211
Schedule of future estimated amortization expense	As of June 30, 2024, future estimated amortization expense for the years ending December 31 is as follows: 2024 $ 20,276 (remaining estimated amortization for 2024) 2025 39,880 2026 37,563 2027 30,410 2028 21,174 Thereafter 109,027

DEBT (Tables)

DEBT (Tables)	6 Months Ended
DEBT (Tables)	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of short-term debt obligations	At June 30, 2024 and December 31, 2023, our notes payable, revolving credit facility and overdrafts consisted of the following: June 30, December 31, Revolving credit facility 6.44% $ 130,000 $ 80,662 Overdrafts 3.08% to 6.00% 6,320 1,132 $ 136,320 $ 81,794
Schedule of long-term obligations	At June 30, 2024 and December 31, 2023, our long-term obligations consisted of the following: June 30, 2024 December 31, 2023 Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2030 $ 16,607 $ 14,988 Senior unsecured notes 3.4%, due in 2024 50,000 50,000 Senior unsecured notes 3.5%, due in 2024 — 100,000 Senior unsecured notes 1.2%, due in 2024 214,220 220,810 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million 399,206 399,154 Finance Lease Liabilities 24,376 26,478 Unamortized debt issuance costs (3,478) (3,816) $ 950,931 $ 1,057,614 Current maturities of long-term obligations (269,399) (376,426) Total long-term obligations $ 681,532 $ 681,188
Schedule of maturities of long-term debt	The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 7, due annually from the current balance sheet date for the next five years and thereafter are: Year One $ 266,123 Year Two 134,218 Year Three 130,330 Year Four 73 Year Five 42 Thereafter 399,247
Schedule of covenants on revolving credit facility and corporate long-term obligations	Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at June 30, 2024 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.29 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 16.97 to 1.00 ________________________________________ (1)

LEASES (Tables)

LEASES (Tables)	6 Months Ended
LEASES (Tables)	Jun. 30, 2024
Leases [Abstract]
Schedule of components of lease expense	The components of lease expense for the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating lease cost $ 4,854 $ 5,277 $ 9,735 $ 10,691 Finance lease cost: Amortization of right-of-use assets $ 1,591 $ 867 $ 3,261 $ 1,778 Interest on lease liabilities 302 295 598 594 Total finance lease cost $ 1,893 $ 1,162 $ 3,859 $ 2,372 Short-term lease and variable lease costs $ 4,998 $ 5,197 $ 10,196 $ 10,109
Schedule of supplemental cash flow information related to leases	Supplemental cash flow information related to leases were as follows: Six Months Ended June 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9,754 $ 10,640 Operating cash flows from finance leases 647 600 Financing cash flows from finance leases 1,821 1,649 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 12,059 $ 6,597 Finance leases 311 352

RETIREMENT AND DEFERRED COMPE_2

RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	6 Months Ended
RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	Jun. 30, 2024
Retirement Benefits [Abstract]
Schedule of components of net periodic benefit cost	Components of Net Periodic Benefit Cost: Domestic Plans Foreign Plans Three Months Ended June 30, 2024 2023 2024 2023 Service cost $ 2,366 $ 2,410 $ 1,603 $ 1,487 Interest cost 2,252 2,157 867 917 Expected return on plan assets (3,130) (3,095) (558) (589) Amortization of net loss — — 257 229 Amortization of prior service cost — — 26 45 Net periodic benefit cost $ 1,488 $ 1,472 $ 2,195 $ 2,089 Domestic Plans Foreign Plans Six Months Ended June 30, 2024 2023 2024 2023 Service cost $ 4,731 $ 4,819 $ 3,233 $ 2,957 Interest cost 4,484 4,315 1,742 1,820 Expected return on plan assets (6,231) (6,189) (1,122) (1,169) Amortization of net loss — — 516 457 Amortization of prior service cost — — 54 88 Net periodic benefit cost $ 2,984 $ 2,945 $ 4,423 $ 4,153

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	6 Months Ended
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	Jun. 30, 2024
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Schedule of changes in accumulated other comprehensive (loss) income by component	Changes in Accumulated Other Comprehensive (Loss) Income by Component: Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Other comprehensive income (loss) before reclassifications 24,129 68 (5,131) 19,066 Amounts reclassified from accumulated other comprehensive income — 387 — 387 Net current-period other comprehensive income (loss) 24,129 455 (5,131) 19,453 Balance - June 30, 2023 $ (304,611) $ (5,496) $ (11,806) $ (321,913) Balance - December 31, 2023 $ (280,082) $ (11,891) $ (16,761) $ (308,734) Other comprehensive (loss) income before reclassifications (65,805) 102 5,509 (60,194) Amounts reclassified from accumulated other comprehensive income — 404 — 404 Net current-period other comprehensive (loss) income (65,805) 506 5,509 (59,790) Balance - June 30, 2024 $ (345,887) $ (11,385) $ (11,252) $ (368,524)
Schedule of reclassifications out of accumulated other comprehensive (loss) income	Reclassifications Out of Accumulated Other Comprehensive (Loss) Income: Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Three Months Ended June 30, 2024 2023 Defined Benefit Pension Plans Amortization of net loss $ 257 $ 229 (1) Amortization of prior service cost 26 45 (1) 283 274 Total before tax (82) (79) Tax impact $ 201 $ 195 Net of tax Total reclassifications for the period $ 201 $ 195 Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Six Months Ended June 30, 2024 2023 Defined Benefit Pension Plans Amortization of net loss $ 516 $ 457 (1) Amortization of prior service cost 54 88 (1) 570 545 Total before tax (166) (158) Tax impact $ 404 $ 387 Net of tax Total reclassifications for the period $ 404 $ 387 ______________________________________________ (1) These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	6 Months Ended
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair value of derivative instruments in the consolidated balance sheets	Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 June 30, 2024 December 31, 2023 Balance Sheet Location Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 949 $ — $ 386 $ — $ 949 $ — $ 386 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 646 $ — $ 221 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 14,901 — 22,199 — $ 14,901 $ 646 $ 22,199 $ 221 __________________________ (1) This cross currency swap agreement is composed of both an interest component and a foreign exchange component.
Schedule of effect of cash flow hedge accounting on accumulated other comprehensive income (loss)	The Effect of Derivatives Designated as Hedging Instruments on Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended June 30, 2024 and 2023 Derivatives Designated as Hedging Instruments Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2024 2023 2024 2023 Cross currency swap agreement: Interest component $ — $ — Interest expense $ — $ — $ (10,061) Foreign exchange component 2,601 3,763 Miscellaneous, net — — (795) $ 2,601 $ 3,763 $ — $ — The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Six Months Ended June 30, 2024 and 2023 Derivatives Designated as Hedging Instruments Amount of Gain Location of Gain Recognized Amount of Gain Total Amount of Affected Income Statement Line Item 2024 2023 2024 2023 Cross currency swap agreement: Interest component $ — $ — Interest expense $ — $ — $ (20,236) Foreign exchange component 5,509 (5,131) Miscellaneous, net — — (1,654) $ 5,509 $ (5,131) $ — $ —
Schedule of effect of derivatives not designated as hedging instruments on the consolidated statements of income	The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2024 and 2023 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ 437 $ 59 $ 437 $ 59 The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2024 and 2023 Derivatives Not Designated Location of Loss Recognized Amount of Loss 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ 140 $ (800) $ 140 $ (800)
Schedule of offsetting derivative assets and liabilities	Gross Amounts Offset in the Statement of Financial Position Net Amounts Presented in the Statement of Financial Position Gross Amounts not Offset in the Statement of Financial Position Gross Amount Financial Instruments Cash Collateral Received Net Amount June 30, 2024 Derivative Assets $ 949 — $ 949 — — $ 949 Total Assets $ 949 — $ 949 — — $ 949 Derivative Liabilities $ 15,547 — $ 15,547 — — $ 15,547 Total Liabilities $ 15,547 — $ 15,547 — — $ 15,547 December 31, 2023 Derivative Assets $ 386 — $ 386 — — $ 386 Total Assets $ 386 — $ 386 — — $ 386 Derivative Liabilities $ 22,420 — $ 22,420 — — $ 22,420 Total Liabilities $ 22,420 — $ 22,420 — — $ 22,420

FAIR VALUE (Tables)

FAIR VALUE (Tables)	6 Months Ended
FAIR VALUE (Tables)	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of fair values of financial assets and liabilities	As of June 30, 2024, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,725 $ 1,725 $ — $ — Foreign exchange contracts (2) 949 — 949 — Convertible notes (3) 5,650 — — 5,650 Total assets at fair value $ 8,324 $ 1,725 $ 949 $ 5,650 Liabilities Foreign exchange contracts (2) $ 646 $ — $ 646 $ — Cross currency swap contract (2) 14,901 — 14,901 — Total liabilities at fair value $ 15,547 $ — $ 15,547 $ — As of December 31, 2023, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,106 $ 1,106 $ — $ — Foreign exchange contracts (2) 386 — 386 — Convertible note (3) 5,650 — — 5,650 Total assets at fair value $ 7,142 $ 1,106 $ 386 $ 5,650 Liabilities Foreign exchange contracts (2) $ 221 $ — $ 221 $ — Cross currency swap contract (2) 22,199 — 22,199 — Total liabilities at fair value $ 22,420 $ — $ 22,420 $ — ________________________________________________ (1) Investment in PureCycle Technologies (“PCT” or “PureCycle”). See Note 18 – Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. (3) Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Condensed Consolidated Balance Sheets.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
STOCK-BASED COMPENSATION (Tables)	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of weighted-average assumptions used to estimate fair value of restricted stock units	Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Six Months Ended June 30, 2024 2023 Fair value per stock award $ 145.79 $ 116.17 Grant date stock price $ 141.00 $ 111.38 Assumptions: Aptar's stock price expected volatility 18.80 % 20.00 % Expected average volatility of peer companies 34.80 % 39.70 % Correlation assumption 30.70 % 33.30 % Risk-free interest rate 4.51 % 3.83 % Dividend yield assumption 1.16 % 1.36 %
Schedule of restricted stock unit activity	A summary of RSU activity as of June 30, 2024 and changes during the six month period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2024 335,874 $ 115.15 514,383 $ 130.10 Granted 117,660 136.61 129,614 145.79 Vested (173,168) 119.27 (97,794) 162.33 Forfeited (2,352) 117.67 (26,886) 146.76 Nonvested at June 30, 2024 278,014 $ 121.51 519,317 $ 127.13 Included in the time-based RSU activity for the six months ended June 30, 2024 are 10,208 units granted to non-employee directors and 11,508 units vested related to non-employee directors.
Schedule of compensation expense, fair value, and intrinsic value related to RSU's	Six Months Ended June 30, 2024 2023 Compensation expense $ 21,966 $ 22,008 Fair value of units vested 34,991 27,178 Intrinsic value of units vested 38,040 31,809
Schedule of share-based payment award, stock options, valuation assumptions	These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: Stock Award Plans: Six Months Ended June 30, 2024 2023 Dividend Yield 1.28 % 1.41 % Expected Stock Price Volatility 17.03 % 16.55 % Risk-free Interest Rate 4.51 % 3.57 % Expected Life of Option (years) 7.0 7.0
Schedule of option activity	A summary of option activity under our stock plans during the six months ended June 30, 2024 is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2024 2,182,784 $ 80.63 19,000 $ 66.59 Granted 249,805 141.00 — — Exercised (377,602) 70.66 (19,000) 66.59 Forfeited or expired (5,185) 93.42 — — Outstanding at June 30, 2024 2,049,802 $ 89.80 — $ — Exercisable at June 30, 2024 1,593,918 $ 78.35 — $ — Weighted-Average Remaining Contractual Term (Years): Outstanding at June 30, 2024 4.2 0.0 Exercisable at June 30, 2024 2.7 0.0 Aggregate Intrinsic Value: Outstanding at June 30, 2024 $ 110,862 $ — Exercisable at June 30, 2024 $ 104,452 $ — Intrinsic Value of Options Exercised During the Six Months Ended: June 30, 2024 $ 25,454 $ 1,394 June 30, 2023 $ 16,886 $ 854
Schedule of compensation expense, and fair value related to options	Six Months Ended June 30, 2024 2023 Compensation expense (included in SG&A) $ 4,376 $ 3,147 Compensation expense (included in Cost of sales) 492 278 Compensation expense, Total $ 4,868 $ 3,425 Compensation expense, net of tax 5,272 3,425 Grant date fair value of options vested 2,306 —

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
EARNINGS PER SHARE (Tables)	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of reconciliation of basic and diluted earnings per share	The reconciliation of basic and diluted earnings per share for the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, 2024 June 30, 2023 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 90,454 $ 90,454 $ 83,072 $ 83,072 Average equivalent shares Shares of common stock 66,312 66,312 65,568 65,568 Effect of dilutive stock-based compensation Stock options 774 — 871 — Restricted stock 489 — 416 — Total average equivalent shares 67,575 66,312 66,855 65,568 Net income per share $ 1.34 $ 1.36 $ 1.24 $ 1.27 Six Months Ended June 30, 2024 June 30, 2023 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 173,558 $ 173,558 $ 137,836 $ 137,836 Average equivalent shares Shares of common stock 66,188 66,188 65,470 65,470 Effect of dilutive stock-based compensation Stock options 783 — 889 — Restricted stock 538 — 389 — Total average equivalent shares 67,509 66,188 66,748 65,470 Net income per share $ 2.57 $ 2.62 $ 2.07 $ 2.11

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
SEGMENT INFORMATION (Tables)	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of financial information regarding the company's reportable segments	Financial information regarding our reporting segments is shown below: Three Months Ended Six Months Ended 2024 2023 2024 2023 Total Sales: Aptar Pharma $ 414,783 $ 391,010 $ 822,273 $ 747,121 Aptar Beauty 328,700 338,404 663,580 671,742 Aptar Closures 176,981 177,471 359,678 357,910 Total Sales $ 920,464 $ 906,885 $ 1,845,531 $ 1,776,773 Less: Intersegment Sales: Aptar Pharma $ 250 $ 310 $ 447 $ 375 Aptar Beauty 7,213 8,817 14,773 15,766 Aptar Closures 2,938 1,852 4,800 4,659 Total Intersegment Sales $ 10,401 $ 10,979 $ 20,020 $ 20,800 Net Sales: Aptar Pharma $ 414,533 $ 390,700 $ 821,826 $ 746,746 Aptar Beauty 321,487 329,587 648,807 655,976 Aptar Closures 174,043 175,619 354,878 353,251 Net Sales $ 910,063 $ 895,906 $ 1,825,511 $ 1,755,973 Adjusted EBITDA (1): Aptar Pharma $ 141,488 $ 125,866 $ 273,666 $ 235,164 Aptar Beauty 44,638 43,100 85,772 80,305 Aptar Closures 27,118 27,772 54,279 53,780 Corporate & Other, unallocated (20,476) (15,501) (42,117) (34,337) Acquisition-related costs (2) (140) — (140) (255) Restructuring Initiatives (3) (2,315) (1,943) (5,795) (13,467) Net unrealized investment (loss) gain (4) (140) 2,891 452 3,079 Depreciation and amortization (64,968) (62,267) (129,317) (121,526) Interest Expense (10,061) (9,688) (20,236) (19,916) Interest Income 3,102 648 6,000 1,320 Income before Income Taxes $ 118,246 $ 110,878 $ 222,564 $ 184,147 ________________________________________________ (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 - Acquisitions and Note 18 – Investments in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the three and six months ended June 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Six Months Ended 2024 2023 2024 2023 Restructuring Initiatives by Plan: Optimization initiative $ 2,315 $ 1,943 $ 5,812 $ 13,483 Prior year initiatives — — (17) (16) Total Restructuring Initiatives $ 2,315 $ 1,943 $ 5,795 $ 13,467 Restructuring Initiatives by Segment: Aptar Pharma $ 65 $ 434 $ 89 $ 1,565 Aptar Beauty 1,199 479 3,909 9,770 Aptar Closures 893 440 1,653 962 Corporate & Other 158 590 144 1,170 Total Restructuring Initiatives $ 2,315 $ 1,943 $ 5,795 $ 13,467 (4) Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).
Schedule of restructuring initiatives	Restructuring Initiatives includes expense items for the three and six months ended June 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Six Months Ended 2024 2023 2024 2023 Restructuring Initiatives by Plan: Optimization initiative $ 2,315 $ 1,943 $ 5,812 $ 13,483 Prior year initiatives — — (17) (16) Total Restructuring Initiatives $ 2,315 $ 1,943 $ 5,795 $ 13,467 Restructuring Initiatives by Segment: Aptar Pharma $ 65 $ 434 $ 89 $ 1,565 Aptar Beauty 1,199 479 3,909 9,770 Aptar Closures 893 440 1,653 962 Corporate & Other 158 590 144 1,170 Total Restructuring Initiatives $ 2,315 $ 1,943 $ 5,795 $ 13,467

INVESTMENT IN EQUITY SECURITI_2

INVESTMENT IN EQUITY SECURITIES (Tables)	6 Months Ended
INVESTMENT IN EQUITY SECURITIES (Tables)	Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of investments in equity securities	Our investment in equity securities consisted of the following: June 30, December 31, Equity Method Investments: BTY $ 32,124 $ 33,090 Sonmol 4,546 4,751 Desotec GmbH 940 905 Other Investments: PureCycle 1,725 1,106 YAT 5,229 5,352 Loop 2,894 2,894 Others 1,069 1,105 $ 48,527 $ 49,203
Schedule of sale of PCT shares related to Purecycle investment	We have sold the following PCT shares related to the PureCycle investment: Shares Sold Proceeds Realized Gain 2021 191,349 $ 2,434 $ 2,000 2022 157,600 $ 1,599 $ 1,213 Q3 2023 510,449 $ 5,604 $ 4,188
Schedule of net investment gain/loss	For the three and six months ended June 30, 2024 and 2023, we recorded the following net investment gain on our investment in PureCycle: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net investment gain $ (140) $ 2,891 $ 452 $ 3,079

RESTRUCTURING INITIATIVES (Tabl

RESTRUCTURING INITIATIVES (Tables)	6 Months Ended
RESTRUCTURING INITIATIVES (Tables)	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of activity associated with optimization initiative	As of June 30, 2024, we have recorded the following activity associated with our optimization initiative: Beginning Reserve at December 31, 2023 Net Charges for the Six Months Ended June 30, 2024 Cash Paid Interest and Ending Reserve at June 30, 2024 Employee severance $ 27,078 $ 2,890 $ (9,179) $ (311) $ 20,478 Professional fees and other costs 2,810 2,922 (2,403) (15) 3,314 Totals $ 29,888 $ 5,812 $ (11,582) $ (326) $ 23,792

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Millions	3 Months Ended	6 Months Ended
	Sep. 30, 2023 USD ($) building	Jun. 30, 2024 USD ($) building	Jun. 30, 2023 USD ($) building
Product Information [Line Items]
Assets held-for-sale			$ 0.7
Number of buildings held before the sale \| building		1	3
Number of buildings sold \| building	2
Gain on sale of buildings	$ 0.8
Supplier finance program obligation, current		$ 36.2
Minimum
Product Information [Line Items]
Supplier finance program payment terms		60 days
Maximum
Product Information [Line Items]
Supplier finance program payment terms		120 days

REVENUE - Revenue by Geographic

REVENUE - Revenue by Geographic Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
REVENUE
Total	$ 910,063	$ 895,906	$ 1,825,511	$ 1,755,973
Aptar Pharma
REVENUE
Total	414,533	390,700	821,826	746,746
Aptar Beauty
REVENUE
Total	321,487	329,587	648,807	655,976
Aptar Closures
REVENUE
Total	174,043	175,619	354,878	353,251
Europe
REVENUE
Total	450,127	478,646	924,519	937,445
Europe \| Aptar Pharma
REVENUE
Total	207,493	208,062	419,668	400,182
Europe \| Aptar Beauty
REVENUE
Total	190,740	211,774	396,930	421,126
Europe \| Aptar Closures
REVENUE
Total	51,894	58,810	107,921	116,137
Domestic
REVENUE
Total	289,820	251,953	567,723	511,021
Domestic \| Aptar Pharma
REVENUE
Total	138,734	113,613	264,544	228,925
Domestic \| Aptar Beauty
REVENUE
Total	66,618	56,940	129,895	115,928
Domestic \| Aptar Closures
REVENUE
Total	84,468	81,400	173,284	166,168
Latin America
REVENUE
Total	77,791	76,049	149,873	141,177
Latin America \| Aptar Pharma
REVENUE
Total	13,301	15,669	25,923	23,866
Latin America \| Aptar Beauty
REVENUE
Total	42,207	39,501	80,394	76,066
Latin America \| Aptar Closures
REVENUE
Total	22,283	20,879	43,556	41,245
Asia
REVENUE
Total	92,325	89,258	183,396	166,330
Asia \| Aptar Pharma
REVENUE
Total	55,005	53,356	111,691	93,773
Asia \| Aptar Beauty
REVENUE
Total	21,922	21,372	41,588	42,856
Asia \| Aptar Closures
REVENUE
Total	$ 15,398	$ 14,530	$ 30,117	$ 29,701

REVENUE - Contract Assets and C

REVENUE - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Contract asset (current)	$ 13,783	$ 18,033
Increase / (decrease) in Contract asset (current)	(4,250)
Contract liability (current)	64,435	60,507
Increase / (decrease) in Contract liability (current)	3,928
Contract liability (long-term)	42,102	$ 37,756
Increase / (decrease) in Contract liability (long-term)	4,346
Revenue recognized previously included in current contract liabilities	60,300
Revenue recognized previously included in current contract liabilities at the beginning of the year	$ 35,900

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Inventories, by component
Raw materials	$ 131,954	$ 145,798
Work in process	176,527	176,191
Finished goods	176,127	191,064
Total	$ 484,608	$ 513,053

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Changes in the carrying amount of goodwill
Goodwill, beginning balance	$ 963,418
Foreign currency exchange effects	(13,343)
Goodwill, ending balance	950,075
Operating segment \| Aptar Pharma
Changes in the carrying amount of goodwill
Goodwill, beginning balance	508,447
Foreign currency exchange effects	(10,089)
Goodwill, ending balance	498,358
Operating segment \| Aptar Beauty
Changes in the carrying amount of goodwill
Goodwill, beginning balance	287,097
Foreign currency exchange effects	(2,585)
Goodwill, ending balance	284,512
Operating segment \| Aptar Closures
Changes in the carrying amount of goodwill
Goodwill, beginning balance	167,874
Foreign currency exchange effects	(669)
Goodwill, ending balance	$ 167,205

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Amortized intangible assets
Gross Carrying Amount	$ 513,055		$ 513,055		$ 520,233
Accumulated Amortization	(254,725)		(254,725)		(237,022)
Net Value	258,330		258,330		283,211
Aggregate amortization expense	$ 10,351	$ 11,131	$ 21,674	$ 22,094
Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	13 years 6 months		13 years 6 months
Patents
Amortized intangible assets
Gross Carrying Amount	$ 7,139		$ 7,139		7,362
Accumulated Amortization	(1,968)		(1,968)		(1,754)
Net Value	$ 5,171		$ 5,171		5,608
Patents \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	10 years		10 years
Acquired technology
Amortized intangible assets
Gross Carrying Amount	$ 140,643		$ 140,643		142,837
Accumulated Amortization	(75,255)		(75,255)		(70,520)
Net Value	$ 65,388		$ 65,388		72,317
Acquired technology \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	11 years 2 months 12 days		11 years 2 months 12 days
Customer relationships
Amortized intangible assets
Gross Carrying Amount	$ 305,349		$ 305,349		308,889
Accumulated Amortization	(135,198)		(135,198)		(124,648)
Net Value	$ 170,151		$ 170,151		184,241
Customer relationships \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	13 years 7 months 6 days		13 years 7 months 6 days
Trademarks and trade names
Amortized intangible assets
Gross Carrying Amount	$ 43,078		$ 43,078		43,932
Accumulated Amortization	(35,188)		(35,188)		(33,368)
Net Value	$ 7,890		$ 7,890		10,564
Trademarks and trade names \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	8 years		8 years
License agreements and other
Amortized intangible assets
Gross Carrying Amount	$ 16,846		$ 16,846		17,213
Accumulated Amortization	(7,116)		(7,116)		(6,732)
Net Value	$ 9,730		$ 9,730		$ 10,481
License agreements and other \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	32 years 8 months 12 days		32 years 8 months 12 days

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 20,276
2025	39,880
2026	37,563
2027	30,410
2028	21,174
Thereafter	$ 109,027

INCOME TAXES (Details)

INCOME TAXES (Details)	3 Months Ended		6 Months Ended
INCOME TAXES (Details)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	23.50%	25.10%	22.10%	25.30%

DEBT - Short-term Debt Obligati

DEBT - Short-term Debt Obligations (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts	$ 136,320	$ 81,794
Revolving credit facility 6.44%
Short-term Debt [Line Items]
Interest rate	6.44%
Notes payable, revolving credit facility and overdrafts	$ 130,000	80,662
Overdrafts 3.08% to 6.00%
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts	$ 6,320	$ 1,132
Overdrafts 3.08% to 6.00% \| Minimum
Short-term Debt [Line Items]
Interest rate	3.08%
Overdrafts 3.08% to 6.00% \| Maximum
Short-term Debt [Line Items]
Interest rate	6%

DEBT - Narrative (Details)

DEBT - Narrative (Details) € in Millions			6 Months Ended
DEBT - Narrative (Details) € in Millions	Jul. 02, 2024 USD ($) extension	Feb. 26, 2024 USD ($)	Jun. 30, 2024 USD ($) extension	Jun. 30, 2024 EUR (€) extension	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)
Line of Credit Facility [Line Items]
Short-term borrowing			$ 136,320,000		$ 81,794,000
Commercial Paper
Line of Credit Facility [Line Items]
Short-term borrowing, maximum borrowing capacity			30,000,000
Short-term borrowing			$ 0		0
Amended Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit facility, number of extensions \| extension			2	2
Line of credit facility, duration of extension (in years)			1 year
Line of credit facility, maximum borrowing capacity			$ 600,000,000
Line of credit facility, increase limit			300,000,000
Long-term line of credit			130,000,000		36,500,000
Compensating balance, amount			0
Amended Revolving Credit Facility \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Long-term line of credit					44,200,000	€ 40
Amended Revolving Credit Facility \| Subsidiaries
Line of Credit Facility [Line Items]
Long-term line of credit			$ 0		0
Amended Revolving Credit Facility Maturing In July 2029 \| Subsequent Event
Line of Credit Facility [Line Items]
Line of credit facility, number of extensions \| extension	2
Line of credit facility, duration of extension (in years)	1 year
Line of credit facility, maximum borrowing capacity	$ 600,000,000
Line of credit facility, increase limit	300,000,000
Amortizing Term Loan Matures In July 2027 \| Subsequent Event
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 330,000,000
Senior Unsecured Notes 3.49% Due In 2024
Line of Credit Facility [Line Items]
Debt instrument, repaid		$ 100,000,000
Interest rate on notes		3.49%
Senior unsecured notes 1.2%, due in 2024
Line of Credit Facility [Line Items]
Interest rate on notes			1.20%	1.20%
Long-term debt, gross			$ 214,000,000	€ 200	$ 220,810,000

DEBT - Long-Term Obligations (D

DEBT - Long-Term Obligations (Details) $ in Thousands, € in Millions	Jun. 30, 2024 USD ($)	Jun. 30, 2024 EUR (€)	Dec. 31, 2023 USD ($)	Jul. 06, 2022	Mar. 07, 2022
Components of the company's debt obligations
Finance Lease Liabilities	$ 24,376		$ 26,478
Unamortized debt issuance costs	(3,478)		(3,816)
Long-term debt and lease obligation, including current maturities	950,931		1,057,614
Current maturities of long-term obligations	(269,399)		(376,426)
Total long-term obligations	681,532		681,188
Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2030
Components of the company's debt obligations
Long-term debt, gross	$ 16,607		14,988
Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2030 \| Minimum
Components of the company's debt obligations
Interest rate on notes	0.10%	0.10%
Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2030 \| Maximum
Components of the company's debt obligations
Interest rate on notes	2.25%	2.25%
Senior unsecured notes 3.4%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 50,000		50,000
Interest rate on notes	3.40%	3.40%
Senior unsecured notes 3.5%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 0		100,000
Interest rate on notes	3.50%	3.50%
Senior unsecured notes 1.2%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 214,000	€ 200	220,810
Interest rate on notes	1.20%	1.20%
Senior unsecured notes 3.6%, due in 2025
Components of the company's debt obligations
Long-term debt, gross	$ 125,000		125,000
Interest rate on notes	3.60%	3.60%
Senior unsecured notes 3.6%, due in 2026
Components of the company's debt obligations
Long-term debt, gross	$ 125,000		125,000
Interest rate on notes	3.60%	3.60%
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million
Components of the company's debt obligations
Long-term debt, gross	$ 399,206		$ 399,154
Interest rate on notes	3.60%	3.60%		3.60%	3.60%
Debt instrument, discount	$ 800

DEBT - Long-Term Maturities (De

DEBT - Long-Term Maturities (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Debt Disclosure [Abstract]
Year One	$ 266,123
Year Two	134,218
Year Three	130,330
Year Four	73
Year Five	42
Thereafter	$ 399,247

DEBT - Covenants (Details)

DEBT - Covenants (Details)	Jun. 30, 2024
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	1.29
Consolidated Interest Coverage Ratio	16.97
Minimum
Line of Credit Facility [Line Items]
Consolidated Interest Coverage Ratio	3
Maximum
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	3.50

LEASES - Components of Lease Ex

LEASES - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Components of lease expense:
Operating lease cost	$ 4,854	$ 5,277	$ 9,735	$ 10,691
Finance lease cost:
Amortization of right-of-use assets	1,591	867	3,261	1,778
Interest on lease liabilities	302	295	598	594
Total finance lease cost	1,893	1,162	3,859	2,372
Short-term lease and variable lease costs	$ 4,998	$ 5,197	$ 10,196	$ 10,109

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 9,754	$ 10,640
Operating cash flows from finance leases	647	600
Financing cash flows from finance leases	1,821	1,649
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	12,059	6,597
Finance leases	$ 311	$ 352

RETIREMENT AND DEFERRED COMPE_3

RETIREMENT AND DEFERRED COMPENSATION PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
United States
Components of net periodic benefit cost:
Service cost	$ 2,366	$ 2,410	$ 4,731	$ 4,819
Interest cost	2,252	2,157	4,484	4,315
Expected return on plan assets	(3,130)	(3,095)	(6,231)	(6,189)
Amortization of net loss	0	0	0	0
Amortization of prior service cost	0	0	0	0
Net periodic benefit cost	1,488	1,472	2,984	2,945
Foreign Plans
Components of net periodic benefit cost:
Service cost	1,603	1,487	3,233	2,957
Interest cost	867	917	1,742	1,820
Expected return on plan assets	(558)	(589)	(1,122)	(1,169)
Amortization of net loss	257	229	516	457
Amortization of prior service cost	26	45	54	88
Net periodic benefit cost	$ 2,195	$ 2,089	$ 4,423	$ 4,153

RETIREMENT AND DEFERRED COMPE_4

RETIREMENT AND DEFERRED COMPENSATION PLANS - Narrative (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)
Changes in the benefit obligations and plan assets
Minimum funding requirements	$ 0
United States
Changes in the benefit obligations and plan assets
Defined benefit plan, plan assets, contributions by employer	0
Foreign Plans
Changes in the benefit obligations and plan assets
Defined benefit plan, plan assets, contributions by employer	$ 700,000

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Changes in Accumulated Other Comprehensive Income by Component (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Accumulated other comprehensive income activity
Balance at the beginning of the period	$ 2,306,824
Other comprehensive income (loss) before reclassifications	(60,194)	$ 19,066
Amounts reclassified from accumulated other comprehensive income	404	387
Net current-period other comprehensive income (loss)	(59,790)	19,453
Balance at the end of the period	2,396,449
Accumulated Other Comprehensive Income/(Loss)
Accumulated other comprehensive income activity
Balance at the beginning of the period	(308,734)	(341,366)
Balance at the end of the period	(368,524)	(321,913)
Foreign Currency
Accumulated other comprehensive income activity
Balance at the beginning of the period	(280,082)	(328,740)
Other comprehensive income (loss) before reclassifications	(65,805)	24,129
Amounts reclassified from accumulated other comprehensive income	0	0
Net current-period other comprehensive income (loss)	(65,805)	24,129
Balance at the end of the period	(345,887)	(304,611)
Defined Benefit Pension Plans
Accumulated other comprehensive income activity
Balance at the beginning of the period	(11,891)	(5,951)
Other comprehensive income (loss) before reclassifications	102	68
Amounts reclassified from accumulated other comprehensive income	404	387
Net current-period other comprehensive income (loss)	506	455
Balance at the end of the period	(11,385)	(5,496)
Derivatives
Accumulated other comprehensive income activity
Balance at the beginning of the period	(16,761)	(6,675)
Other comprehensive income (loss) before reclassifications	5,509	(5,131)
Amounts reclassified from accumulated other comprehensive income	0	0
Net current-period other comprehensive income (loss)	5,509	(5,131)
Balance at the end of the period	$ (11,252)	$ (11,806)

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Reclassifications From Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Amount Reclassified from Accumulated Other Comprehensive Income
Total before tax	$ (118,246)	$ (110,878)	$ (222,564)	$ (184,147)
Tax impact	27,788	27,831	49,173	46,514
Total reclassifications for the period	(90,458)	(83,047)	(173,391)	(137,633)
Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Total reclassifications for the period	201	195	404	387
Defined Benefit Pension Plans \| Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Amortization of net loss	257	229	516	457
Amortization of prior service cost	26	45	54	88
Total before tax	283	274	570	545
Tax impact	(82)	(79)	(166)	(158)
Total reclassifications for the period	$ 201	$ 195	$ 404	$ 387

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) $ in Thousands, € in Millions	Jul. 06, 2022 EUR (€)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 06, 2022 USD ($)	Jul. 06, 2022 EUR (€)	Mar. 07, 2022 USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		$ 949	$ 386
Derivative Liabilities		15,547	22,420
Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		949	386
Derivative Liabilities		646	221
Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liabilities		0	0
Cross Currency Swap Contract \| Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, term of contract	7 years
Amount hedged				$ 203,000	€ 200
Derivative fixed interest rate				2.5224%	2.5224%
Derivative, annual fixed interest payments receivable				$ 3,700
Cash flow hedge derivative instrument liability at fair value		14,900
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount		73,000
Foreign Exchange Contracts \| Prepaid and other \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		949	386
Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liabilities		$ 646	$ 221
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt instrument, face amount						$ 400,000
Interest rate on notes		3.60%		3.60%	3.60%	3.60%
Debt instrument, periodic payment \| €	€ 2.5

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Fair Value of Derivative Instruments in the Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value of Derivative Instruments
Derivative Assets	$ 949	$ 386
Derivative Liabilities	15,547	22,420
Derivatives Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	0	0
Derivative Liabilities	14,901	22,199
Derivatives Designated as Hedging Instruments \| Foreign Exchange Contracts \| Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	0	0
Derivatives Designated as Hedging Instruments \| Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	0	0
Derivatives Designated as Hedging Instruments \| Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	14,901	22,199
Derivatives not Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	949	386
Derivative Liabilities	646	221
Derivatives not Designated as Hedging Instruments \| Foreign Exchange Contracts \| Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	949	386
Derivatives not Designated as Hedging Instruments \| Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	646	221
Derivatives not Designated as Hedging Instruments \| Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	$ 0	$ 0

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Derivative instruments, gain or (loss)
Interest expense	$ (10,061)	$ (9,688)	$ (20,236)	$ (19,916)
Miscellaneous expense, net	(795)	(173)	(1,654)	(1,344)
Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	2,601	3,763	5,509	(5,131)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	0	0	0	0
Changes in cross currency swap: interest component \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Interest expense	(10,061)		(20,236)
Changes in cross currency swap: interest component \| Interest expense \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	0	0	0	0
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	0	0	0	0
Changes in cross currency swap: foreign exchange component \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Miscellaneous expense, net	(795)		(1,654)
Changes in cross currency swap: foreign exchange component \| Miscellaneous, net \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	2,601	3,763	5,509	(5,131)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	$ 0	$ 0	$ 0	$ 0

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of (Loss) Gain Recognized in Income on Derivatives	$ 437	$ 59	$ 140	$ (800)
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of (Loss) Gain Recognized in Income on Derivatives	$ 437	$ 59	$ 140	$ (800)

DERIVATIVE INSTRUMENTS AND HE_7

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Derivative Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Derivative Assets
Gross Amount	$ 949	$ 386
Gross Amounts Offset in the Statement of Financial Position	0	0
Net Amounts Presented in the Statement of Financial Position	949	386
Gross Amounts not Offset in the Statement of Financial Position, Financial Instruments	0	0
Gross Amounts not Offset in the Statement of Financial Position, Cash Collateral Received	0	0
Net Amount	$ 949	$ 386
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Prepaid and other	Prepaid and other
Derivative Liabilities
Gross Amount	$ 15,547	$ 22,420
Gross Amounts Offset in the Statement of Financial Position	0	0
Net Amounts Presented in the Statement of Financial Position	15,547	22,420
Gross Amounts not Offset in the Statement of Financial Position, Financial Instruments	0	0
Gross Amounts not Offset in the Statement of Financial Position, Cash Collateral Received	0	0
Net Amount	$ 15,547	$ 22,420
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accounts payable, accrued and other liabilities	Accounts payable, accrued and other liabilities

FAIR VALUE - Fair Value of Fina

FAIR VALUE - Fair Value of Financial Assets and Liabilities (Details) - Assets and liabilities measured at fair value on recurring basis - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Assets
Investment in equity securities	$ 1,725	$ 1,106
Foreign exchange contracts	949	386
Convertible note	5,650	5,650
Total assets at fair value	8,324	7,142
Liabilities
Foreign exchange contracts	646	221
Cross currency swap contract	14,901	22,199
Total liabilities at fair value	15,547	22,420
Level 1
Assets
Investment in equity securities	1,725	1,106
Foreign exchange contracts	0	0
Convertible note	0	0
Total assets at fair value	1,725	1,106
Liabilities
Foreign exchange contracts	0	0
Cross currency swap contract	0	0
Total liabilities at fair value	0	0
Level 2
Assets
Investment in equity securities	0	0
Foreign exchange contracts	949	386
Convertible note	0	0
Total assets at fair value	949	386
Liabilities
Foreign exchange contracts	646	221
Cross currency swap contract	14,901	22,199
Total liabilities at fair value	15,547	22,420
Level 3
Assets
Investment in equity securities	0	0
Foreign exchange contracts	0	0
Convertible note	5,650	5,650
Total assets at fair value	5,650	5,650
Liabilities
Foreign exchange contracts	0	0
Cross currency swap contract	0	0
Total liabilities at fair value	$ 0	$ 0

FAIR VALUE - Narrative (Details

FAIR VALUE - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair value of long-term obligations	$ 614.5	$ 620.7

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Indemnification agreements
Commitments and contingencies
Liabilities recorded under indemnification agreements	$ 0	$ 0
Tax Assessment
Commitments and contingencies
Loss contingency estimate of possible loss	13,000,000
Loss contingency liability recorded	0
Tax Assessment, Interest and Penalties \| Minimum
Commitments and contingencies
Loss contingency estimate of possible loss	5,000,000
Tax Assessment, Interest and Penalties \| Maximum
Commitments and contingencies
Loss contingency estimate of possible loss	$ 6,000,000

STOCK REPURCHASE PROGRAM (Detai

STOCK REPURCHASE PROGRAM (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Apr. 18, 2019
Stock repurchase program
Common stock repurchased (retired and held in treasury) (in shares)	34	81	120	252
Common stock repurchased (retired and held in treasury)	$ 5.1	$ 9.3	$ 17.1	$ 29
Remaining authorized repurchase amount	$ 43.5		$ 43.5
Stock Repurchase Program April 18, 2019
Stock repurchase program
Share repurchases authorized amount					$ 350

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average fair value of stock options granted (in dollars per share)	$ 36.07
Proceeds from stock option exercises	$ 27,797	$ 24,342
Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average fair value of stock options granted (in dollars per share)		$ 19.84
Received stock options exercise price percentage		110%
Non Executive Officer Employees
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average fair value of stock options granted (in dollars per share)		$ 24.23
Time-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSU's granted (in shares)	117,660
RSUs vested (in shares)	173,168
Time-Based RSUs \| Director Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award
RSU's granted (in shares)	10,208
RSUs vested (in shares)	11,508
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSU's granted (in shares)	129,614
RSUs vested (in shares)	97,794
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Tax benefit	$ 7,100	$ 5,400
Unrecognized compensation expense	$ 53,300
Weighted-average period cost will be recognized over	2 years
Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
Tax benefit	$ 6,200	4,300
Unrecognized compensation expense	$ 6,000
Weighted-average period cost will be recognized over	2 years 3 months 18 days
Expiration period (in years)	10 years
Proceeds from stock option exercises	$ 27,800	$ 24,300

STOCK-BASED COMPENSATION - Assu

STOCK-BASED COMPENSATION - Assumptions Used (Details) - Performance-Based RSUs - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award
Fair value per stock award (in dollars per share)	$ 145.79	$ 116.17
Grant date stock price (in dollars per share)	$ 141	$ 111.38
Aptar's stock price expected volatility	18.80%	20%
Expected average volatility of peer companies	34.80%	39.70%
Correlation assumption	30.70%	33.30%
Risk-free interest rate	4.51%	3.83%
Dividend yield assumption	1.16%	1.36%

STOCK-BASED COMPENSATION - Rest

STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Time-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) \| shares	335,874
Granted (in shares) \| shares	117,660
Vested (in shares) \| shares	(173,168)
Forfeited (in shares) \| shares	(2,352)
Nonvested outstanding ending balance (in shares) \| shares	278,014
Weighted Average Grant-Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) \| $ / shares	$ 115.15
Granted, Weighted average grant date fair value (in dollars per share) \| $ / shares	136.61
Vested, Weighted average grant date fair value (in dollars per share) \| $ / shares	119.27
Forfeited, Weighted average grant date fair value (in dollars per share) \| $ / shares	117.67
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) \| $ / shares	$ 121.51
Performance-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) \| shares	514,383
Granted (in shares) \| shares	129,614
Vested (in shares) \| shares	(97,794)
Forfeited (in shares) \| shares	(26,886)
Nonvested outstanding ending balance (in shares) \| shares	519,317
Weighted Average Grant-Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) \| $ / shares	$ 130.10
Granted, Weighted average grant date fair value (in dollars per share) \| $ / shares	145.79
Vested, Weighted average grant date fair value (in dollars per share) \| $ / shares	162.33
Forfeited, Weighted average grant date fair value (in dollars per share) \| $ / shares	146.76
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) \| $ / shares	$ 127.13

STOCK-BASED COMPENSATION - Comp

STOCK-BASED COMPENSATION - Compensation Expense (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 21,966	$ 22,008
Fair value of units vested	34,991	27,178
Intrinsic value of units vested	38,040	31,809
Options
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	4,868	3,425
Compensation expense, net of tax	5,272	3,425
Grant date fair value of options vested	2,306	0
Options \| Compensation expense (included in SG&A)
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	4,376	3,147
Options \| Compensation expense (included in Cost of sales)
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 492	$ 278

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of Option Activity (Details) - Options - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Stock Awards Plans
Assumptions used to estimate fair value of stock options granted
Dividend yield assumption	1.28%	1.41%
Expected Stock Price Volatility	17.03%	16.55%
Risk-free interest rate	4.51%	3.57%
Expected Life of Option (years)	7 years	7 years
Stock options activity
Outstanding at the beginning of the period (in shares)	2,182,784
Granted (in shares)	249,805
Exercised (in shares)	(377,602)
Forfeited or expired (in shares)	(5,185)
Outstanding at the end of the period (in shares)	2,049,802
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 80.63
Options granted, Weighted average exercise price (in dollars per share)	141
Options exercised, Weighted average exercise price (in dollars per share)	70.66
Options forfeited or expired, Weighted average exercise price (in dollars per share)	93.42
Outstanding at the end of the period (in dollars per share)	$ 89.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	1,593,918
Options exercisable, Weighted average exercise price (in dollars per share)	$ 78.35
Options outstanding, Weighted average remaining contractual term (in years)	4 years 2 months 12 days
Options exercisable, Weighted average remaining contractual term (in years)	2 years 8 months 12 days
Options outstanding, Aggregate intrinsic value	$ 110,862
Options exercisable, Aggregate intrinsic value	104,452
Options exercised, Intrinsic value, at end of period	$ 25,454	$ 16,886
Director Stock Option Plans
Stock options activity
Outstanding at the beginning of the period (in shares)	19,000
Granted (in shares)	0
Exercised (in shares)	(19,000)
Forfeited or expired (in shares)	0
Outstanding at the end of the period (in shares)	0
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 66.59
Options granted, Weighted average exercise price (in dollars per share)	0
Options exercised, Weighted average exercise price (in dollars per share)	66.59
Options forfeited or expired, Weighted average exercise price (in dollars per share)	0
Outstanding at the end of the period (in dollars per share)	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	0
Options exercisable, Weighted average exercise price (in dollars per share)	$ 0
Options outstanding, Weighted average remaining contractual term (in years)	0 years
Options exercisable, Weighted average remaining contractual term (in years)	0 years
Options outstanding, Aggregate intrinsic value	$ 0
Options exercisable, Aggregate intrinsic value	0
Options exercised, Intrinsic value, at end of period	$ 1,394	$ 854

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Consolidated operations
Income available to common stockholders, diluted	$ 90,454	$ 83,072	$ 173,558	$ 137,836
Income available to common stockholders, basic	$ 90,454	$ 83,072	$ 173,558	$ 137,836
Average equivalent shares (in Shares)
Basic (in shares)	66,312	65,568	66,188	65,470
Effect of dilutive stock-based compensation
Diluted (in shares)	67,575	66,855	67,509	66,748
Net income per share
Net income per share, diluted (in dollars per share)	$ 1.34	$ 1.24	$ 2.57	$ 2.07
Net income per share, basic (in dollars per share)	$ 1.36	$ 1.27	$ 2.62	$ 2.11
Stock options
Effect of dilutive stock-based compensation
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares)	774	871	783	889
Restricted stock
Effect of dilutive stock-based compensation
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares)	489	416	538	389

SEGMENT INFORMATION - Schedule

SEGMENT INFORMATION - Schedule of Reportable Segments (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) segment	Jun. 30, 2023 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment			3
Financial information regarding the Company's reportable segments
Net Sales	$ 910,063	$ 895,906	$ 1,825,511	$ 1,755,973
Acquisition-related costs	(140)	0	(140)	(255)
Restructuring Initiatives	(2,315)	(1,943)	(5,795)	(13,467)
Net unrealized investment (loss) gain	(140)	2,891	452	3,079
Depreciation and amortization	(64,968)	(62,267)	(129,317)	(121,526)
Interest Expense	(10,061)	(9,688)	(20,236)	(19,916)
Interest Income	3,102	648	6,000	1,320
Income before Income Taxes	118,246	110,878	222,564	184,147
Optimization initiative
Financial information regarding the Company's reportable segments
Restructuring Initiatives	(2,315)	(1,943)	(5,812)	(13,483)
Prior year initiatives
Financial information regarding the Company's reportable segments
Restructuring Initiatives	0	0	17	16
Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	414,533	390,700	821,826	746,746
Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	321,487	329,587	648,807	655,976
Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	174,043	175,619	354,878	353,251
Operating segment
Financial information regarding the Company's reportable segments
Net Sales	920,464	906,885	1,845,531	1,776,773
Operating segment \| Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	414,783	391,010	822,273	747,121
Adjusted EBITDA	141,488	125,866	273,666	235,164
Restructuring Initiatives	(65)	(434)	(89)	(1,565)
Operating segment \| Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	328,700	338,404	663,580	671,742
Adjusted EBITDA	44,638	43,100	85,772	80,305
Restructuring Initiatives	(1,199)	(479)	(3,909)	(9,770)
Operating segment \| Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	176,981	177,471	359,678	357,910
Adjusted EBITDA	27,118	27,772	54,279	53,780
Restructuring Initiatives	(893)	(440)	(1,653)	(962)
Intersegment
Financial information regarding the Company's reportable segments
Net Sales	10,401	10,979	20,020	20,800
Intersegment \| Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	250	310	447	375
Intersegment \| Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	7,213	8,817	14,773	15,766
Intersegment \| Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	2,938	1,852	4,800	4,659
Corporate & Other, unallocated
Financial information regarding the Company's reportable segments
Adjusted EBITDA	(20,476)	(15,501)	(42,117)	(34,337)
Restructuring Initiatives	$ (158)	$ (590)	$ (144)	$ (1,170)

ACQUISITIONS (Details)

ACQUISITIONS (Details) - USD ($) $ in Thousands		6 Months Ended
ACQUISITIONS (Details) - USD ($) $ in Thousands	Mar. 01, 2023	Jun. 30, 2024	Jun. 30, 2023
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow		$ 0	$ 10,910
iD SCENT
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow	$ 9,400
Cash acquired	1,400
Gulf Closures
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow	1,500
Cash acquired	$ 1,200
Percentage of interest acquired	80%
Valuation of full company equity of acquired company	$ 3,300
Non-controlling interest value	$ 700

INVESTMENT IN EQUITY SECURITI_3

INVESTMENT IN EQUITY SECURITIES - Schedule of Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Total equity method investments and other investments	$ 48,527	$ 49,203
BTY
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	32,124	33,090
Sonmol
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	4,546	4,751
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	940	905
PureCycle
Schedule of Equity Method Investments [Line Items]
Other Investments:	1,725	1,106
YAT
Schedule of Equity Method Investments [Line Items]
Other Investments:	5,229	5,352
Loop
Schedule of Equity Method Investments [Line Items]
Other Investments:	2,894	2,894
Others
Schedule of Equity Method Investments [Line Items]
Other Investments:	$ 1,069	$ 1,105

INVESTMENT IN EQUITY SECURITI_4

INVESTMENT IN EQUITY SECURITIES - Narrative (Details) € in Thousands						6 Months Ended		12 Months Ended	27 Months Ended	60 Months Ended
	Apr. 26, 2024 USD ($)	Dec. 10, 2023 USD ($)	Jul. 07, 2021 USD ($)	Apr. 01, 2020 USD ($)	Jan. 01, 2020 USD ($) company	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2009 EUR (€)	Mar. 31, 2021 USD ($)	Dec. 31, 2023 USD ($)
Schedule of Equity Method Investments [Line Items]
Investment impairment						$ 0	$ 0
Jinyu
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment		40%
Investment in equity securities		$ 84,000,000
BTY
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					49%
Investment in equity securities					$ 32,000,000
Number of related companies \| company					3
Initial lock-up period (in years)					5 years
Second lock-up period (in years)					3 years
Purchases from related party						5,800,000	$ 7,600,000
Accounts payable and other accrued liabilities						$ 2,400,000				$ 1,800,000
BTY \| Call Option \| Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					26%
BTY \| Call Option \| Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					31%
Sonmol
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment				30%
Investment in equity securities				$ 5,000,000
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment								23%
Investment in equity securities \| €								€ 574
Loop \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Investment in equity securities										$ 2,900,000
PureCycle
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage									0.01
PureCycle \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Investment in equity securities									$ 3,000,000
Equity received in exchange for services	$ 200,000								$ 700,000
YAT
Schedule of Equity Method Investments [Line Items]
Investment in equity securities			$ 5,900,000
Investment ownership percentage			0.10

INVESTMENT IN EQUITY SECURITI_5

INVESTMENT IN EQUITY SECURITIES - Purecycle Investment (Details) - PureCycle - Preferred stock - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Shares Sold (in shares)	510,449	157,600	191,349
Proceeds	$ 5,604	$ 1,599	$ 2,434
Realized Gain	$ 4,188	$ 1,213	$ 2,000

INVESTMENT IN EQUITY SECURITI_6

INVESTMENT IN EQUITY SECURITIES - Net Investment Gain/Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Equity Method Investments [Line Items]
Net investment (loss) gain	$ (140)	$ 2,891	$ 452	$ 3,079
PureCycle \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Net investment (loss) gain	$ (140)	$ 2,891	$ 452	$ 3,079

RESTRUCTURING INITIATIVES - Nar

RESTRUCTURING INITIATIVES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring initiatives	$ 2,315	$ 1,943	$ 5,795	$ 13,467
Optimization Plan
Restructuring Cost and Reserve [Line Items]
Restructuring initiatives	2,300	$ 1,900	5,812	$ 13,500
Cumulative expense incurred	$ 57,500		$ 57,500

RESTRUCTURING INITIATIVES - Act

RESTRUCTURING INITIATIVES - Activity associated with optimization initiative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restructuring reserve
Net Charges	$ 2,315	$ 1,943	$ 5,795	$ 13,467
Optimization Plan
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			29,888
Net Charges	2,300	$ 1,900	5,812	$ 13,500
Cash Paid			(11,582)
Interest and FX Impact			(326)
Restructuring reserve, balance at the end of the period	23,792		23,792
Employee severance \| Optimization Plan
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			27,078
Net Charges			2,890
Cash Paid			(9,179)
Interest and FX Impact			(311)
Restructuring reserve, balance at the end of the period	20,478		20,478
Professional fees and other costs \| Optimization Plan
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			2,810
Net Charges			2,922
Cash Paid			(2,403)
Interest and FX Impact			(15)
Restructuring reserve, balance at the end of the period	$ 3,314		$ 3,314